Healthcare pharma pipeline catalysts · Thesis · Arbora ↑

Johnson & Johnson, Merck, and Pfizer are each generating positive late-stage clinical data that could unlock new revenue streams: J&J presented real-world data on nipocalimab for myasthenia gravis, Merck reported positive Phase 3 results for tulisokibart in ulcerative colitis, and Pfizer received an FDA approval in late June. These pipeline catalysts are arriving at a time when large-cap pharma trades at a discount to the broader market, offering a risk-reward setup where binary clinical events can re-rate individual names sharply. The cluster of near-simultaneous positive readouts across three companies suggests a broader favorable regulatory and clinical environment for large-cap pharma.

Published 2026-07-06 Updated 2026-09-27

Core thesis

Simultaneous late-stage pipeline successes at J&J, Merck, and Pfizer — arriving while large-cap pharma trades at a valuation discount to the broader market — create a compelling re-rating opportunity as binary clinical and regulatory catalysts convert pipeline optionality into tangible new revenue streams.

Causal chain

Late-stage clinical success → regulatory de-risking → revenue visibility expansion → valuation re-rating

Revenue visibility expansion compresses the discount rate applied to earnings. Once a drug clears Phase 3 or receives FDA approval, sell-side models can incorporate peak-sales estimates with greater confidence. This mechanically lifts price targets and consensus estimates, attracting incremental institutional buyers who were previously sidelined by binary risk. For J&J, nipocalimab addresses a rare neuromuscular disease with limited competition; for Merck, tulisokibart enters the large and growing inflammatory bowel disease market already validated by biologics; for Pfizer, the Ibrance label expansion deepens an already-commercialized franchise.
Sector-wide positive readout cluster signals a favorable regulatory and clinical environment. When multiple large-cap names report positive outcomes near-simultaneously, it suggests the current FDA review posture and clinical trial execution environment are constructive. This reduces the perceived systemic risk across the sector, encouraging multiple expansion not just for the three names but for large-cap pharma broadly — a tailwind that amplifies individual stock moves.
Valuation discount to the broader market provides asymmetric entry. Large-cap pharma already trading at a discount means the starting multiple is compressed, so positive catalysts do not need to overcome expensive valuations to generate returns. The re-rating path is shorter: incremental good news closes the discount gap rather than requiring premium expansion. This asymmetry — limited downside from an already-discounted base, meaningful upside from catalyst-driven re-rating — is the structural setup underpinning the thesis.
Pipeline momentum attracts capital rotation. As these names demonstrate execution across R&D, regulatory affairs, and commercial readiness, generalist and healthcare-specialist funds that had underweighted large-cap pharma due to patent cliff concerns and pipeline uncertainty have a fundamental reason to rotate back in, sustaining price appreciation beyond the initial catalyst pop.

Key drivers

Nipocalimab (J&J) real-world data validation: Real-world evidence presented at a major European conference carries particular weight because it reflects outcomes in heterogeneous patient populations beyond controlled trial conditions, strengthening the commercial and reimbursement narrative for generalized myasthenia gravis — a rare disease with high unmet need and favorable pricing dynamics.
Tulisokibart Phase 3 success (Merck): Ulcerative colitis is a large, chronic, and underserved indication; a Phase 3 win positions Merck to diversify revenue beyond KEYTRUDA, addressing long-standing investor concern about oncology concentration risk. The simultaneous KEYTRUDA approval news further reinforces Merck's broad pipeline execution.
Pfizer FDA approval and hedge fund accumulation: The Ibrance milestone, combined with reported hedge fund interest citing pipeline upside and dividend yield, suggests institutional smart money is already positioning — a demand-side catalyst that can sustain price support independent of further clinical news.
Sector valuation discount: Large-cap pharma trading below broader market multiples means the risk-reward is skewed favorably; positive catalysts re-rate from a low base, amplifying percentage returns relative to a fairly-valued or expensive entry point.
Cluster effect of near-simultaneous readouts: Three positive signals across three companies in a compressed timeframe reduces the probability that any single outcome is idiosyncratic luck, suggesting systemic tailwinds in clinical execution and regulatory receptivity.
High signal and confidence scores across evidence: All three cited catalysts carry signal scores of 0.7–0.85 and confidence scores of 0.75–0.85, indicating the underlying data quality and market relevance of these events are above average for pipeline news.

Risks and counter-case

Commercial execution risk post-approval: Positive clinical data and FDA approval do not guarantee commercial success. Pricing negotiations, formulary access, payer pushback, and competitive dynamics in each indication (particularly ulcerative colitis, which already has established biologics) could limit peak sales relative to expectations, capping the re-rating.
Patent cliff overhang remains unresolved: Large-cap pharma's valuation discount to the market is partly structural, reflecting known patent expirations on blockbuster drugs. Pipeline wins for nipocalimab, tulisokibart, and Ibrance may not be large enough in isolation to fully offset revenue losses from LOE events, limiting the magnitude of multiple expansion.
Binary risk cuts both ways: The same clinical environment that produced three positive readouts could produce negative surprises in subsequent pipeline assets. A late-stage failure at any of these three companies — particularly for Merck given KEYTRUDA concentration — could reverse sentiment sharply.
Regulatory environment can shift: FDA approval posture is not static. Increased scrutiny, advisory committee rejections, or label restrictions on any of these drugs could invalidate the thesis that a broadly favorable regulatory environment exists.
Macro and sector rotation risk: If interest rates rise or risk appetite shifts toward cyclicals, the defensive premium that large-cap pharma commands could compress further, overwhelming pipeline-driven upside with multiple contraction.
Pfizer-specific credibility risk: Pfizer's post-COVID revenue normalization and prior pipeline disappointments mean the market may apply a higher skepticism discount to its pipeline news, limiting the re-rating response to the Ibrance approval relative to J&J or Merck.
Thesis invalidation trigger: If any of the three drugs fails to receive full approval, receives a narrow label that limits addressable market, or faces early commercial underperformance, the cluster narrative breaks down and the thesis reverts to a single-stock story with less compelling risk-reward.

What to watch

FDA action dates and PDUFA dates for nipocalimab (J&J) and tulisokibart (Merck) — the conversion of Phase 3 data into formal approvals is the next binary event that will drive the most significant price moves.
Merck tulisokibart NDA/BLA filing timeline — submission and acceptance by FDA would confirm the regulatory pathway is on track and provide a concrete catalyst schedule for investors.
J&J nipocalimab reimbursement and payer coverage decisions — particularly in Europe given the conference venue, as early formulary wins signal commercial viability and pricing power in rare disease.
Pfizer Ibrance prescription volume trends and market share data following the label expansion — early commercial uptake data (IMS/IQVIA scripts) will confirm whether the FDA milestone translates into incremental revenue.
Sell-side consensus estimate revisions for JNJ, MRK, and PFE following these readouts — upward EPS and revenue revisions are the mechanical driver of re-rating and serve as a leading indicator of institutional repositioning.
Large-cap pharma sector P/E relative to S&P 500 — narrowing of the valuation discount would confirm the re-rating thesis is playing out; a widening discount despite positive news would be a warning signal.
Competitor pipeline readouts in ulcerative colitis and myasthenia gravis — adverse data from competitors could validate the disease area, while positive competitor data could intensify pricing pressure and limit tulisokibart's and nipocalimab's commercial opportunity.
Hedge fund 13F filings — given cited hedge fund accumulation in PFE, subsequent filings will reveal whether institutional positioning is building or unwinding, providing a sentiment check on the smart-money thesis.

Sources

Merck (MRK) Wins New KEYTRUDA Approvals As Tulisokibart Clears A Phase 3 Test 2026-07-04
Merck reported positive Phase 3 results for tulisokibart in moderate-to-severe ulcerative colitis — a significant pipeline catalyst.
Johnson & Johnson (JNJ) Unveils New IMAAVY Data With Broader Reach In View 2026-07-05
J&J presented positive real-world and clinical data on nipocalimab for generalized myasthenia gravis at a major European conference.
Pfizer Inc. (PFE): A Top Dividend Stock to Buy According to Hedge Funds amid Ibrance FDA Milestone 2026-07-05
FDA approved a new Pfizer drug use in late June, cited as a reason hedge funds favor PFE as a dividend stock with pipeline upside.
Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year 2026-07-05
Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year — The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S.
Yahoo Finance 2026-07-06
Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into Earnings
Intuitive Surgical Stock Looks Weighed Down. Its After-Hours Growth Says Otherwise. 2026-07-06
Intuitive Surgical Stock Looks Weighed Down. Its After-Hours Growth Says Otherwise.
Yahoo Finance 2026-07-06
MEDevice Boston 2026: East Coast's Top Medical Device Conference Opens Registration for August 26-27 Event
Yahoo Finance 2026-07-06
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
Yahoo Finance 2026-07-06
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
Yahoo Finance 2026-07-06
Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio 2026-07-06
3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio
What Eli Lilly Stock Said When It Had Too Much Business 2026-07-06
What Eli Lilly Stock Said When It Had Too Much Business
Yahoo Finance 2026-07-06
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
Yahoo Finance 2026-07-06
3 Healthcare ETFs to Own in a Choppy Stock Market
The Income Ladder: What It Takes To Go From $250 To $5,000 A Month 2026-07-06
The Income Ladder: What It Takes To Go From $250 To $5,000 A Month — The personal saving rate was 3.0% in May 2026, while average annual household expenditures reached $78,535 in the 2024 Consumer Expenditure Survey.
Yahoo Finance 2026-07-06
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Yahoo Finance 2026-07-06
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Only 3 Under-the-Radar Dividend Stocks Survived This Brutal Screen. One Could Rally 115%. 2026-07-06
Only 3 Under-the-Radar Dividend Stocks Survived This Brutal Screen. One Could Rally 115%.
Yahoo Finance 2026-07-06
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade — Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.
Yahoo Finance 2026-07-06
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why — Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.
How To Target A 10% Yield While Catching The BSX Stock Knife? 2026-07-07
How To Target A 10% Yield While Catching The BSX Stock Knife?
Yahoo Finance 2026-07-07
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
Yahoo Finance 2026-07-07
Halifax Group Names Rob Holcomb as Operating Executive
The $1,500-A-Month Portfolio: Conservative, Moderate, And High-Yield Paths Compared 2026-07-07
The $1,500-A-Month Portfolio: Conservative, Moderate, And High-Yield Paths Compared — Replacing $1,500 a month in portfolio income looks simple until yield enters the equation. At a 3.5% yield, you need roughly $514,000 invested. At 6%, the target falls to $300,000.
Yahoo Finance 2026-07-07
2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them
Yahoo Finance 2026-07-07
Former Pfizer Building Is Crumbling—Just as the Stock Has — The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the index, at more than 7%. Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over
Yahoo Finance 2026-07-07
Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update — The IMAAVY update lands at a time when Johnson & Johnson shares have strong momentum, with an 11.41% 30 day share price return and a 25.07% year to date share price return, alongside a 71.19% 1 year total shareholder...
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now 2026-07-07
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now — For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ...
Yahoo Finance 2026-07-07
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Unusual Put Option Activity in Johnson & Johnson After JNJ Stock's Recent Runup 2026-07-07
Unusual Put Option Activity in Johnson & Johnson After JNJ Stock's Recent Runup
The Wide Divide Ahead For Eli Lilly Stock 2026-07-08
The Wide Divide Ahead For Eli Lilly Stock
Yahoo Finance 2026-07-08
Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July 2026-07-08
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July — The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist. If you have $1,000 to put to work, three NYSE-listed names stand out on valuation, cash flow, and payout ...
Yahoo Finance 2026-07-08
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Yahoo Finance 2026-07-08
How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum — On June 24, Pfizer said its board declared a $0.43 third-quarter dividend on the company’s common stock, payable September 1 to holders of record at the close of business on July 24.
Yahoo Finance 2026-07-08
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Yahoo Finance 2026-07-08
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
Yahoo Finance 2026-07-08
Will New KEYTRUDA Breast and Bladder Cancer Approvals Redefine Merck’s (MRK) Post-Exclusivity Narrative?
Yahoo Finance 2026-07-08
Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds
Yahoo Finance 2026-07-08
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
Just How Wide Is The Path Ahead For Intuitive Surgical Stock? 2026-07-08
Just How Wide Is The Path Ahead For Intuitive Surgical Stock?
Yahoo Finance 2026-07-08
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
Yahoo Finance 2026-07-08
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
Yahoo Finance 2026-07-08
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
Yahoo Finance 2026-07-08
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors — Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.
Yahoo Finance 2026-07-08
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
How A 2.5% Yield Can Turn Into A Retirement Paycheck That Keeps Growing 2026-07-08
How A 2.5% Yield Can Turn Into A Retirement Paycheck That Keeps Growing — The average American household spent $78,535 in 2024, according to the latest Bureau of Labor Statistics Consumer Expenditure Survey. Round that to $80,000, and you have a useful starting point for the retirement paycheck many households may need to replace.
Yahoo Finance 2026-07-08
Former Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilities
Yahoo Finance 2026-07-09
Dual-Energy EP Catheter Approval Could Be A Game Changer For Johnson & Johnson (JNJ)
JPMorgan resets LLY stock target on drug demand 2026-07-09
JPMorgan resets LLY stock target on drug demand
Yahoo Finance 2026-07-09
Southeast Asia Oncology Drug Access Market Now Available; Profiles Roche, AstraZeneca, Merck, and Other Key Peers
Make Your AMGN Shares Pay You 8.7% While You Hold Them 2026-07-09
Make Your AMGN Shares Pay You 8.7% While You Hold Them
Yahoo Finance 2026-07-09
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
Yahoo Finance 2026-07-09
Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump
The Wide Chasm Priced Into Boston Scientific Stock 2026-07-09
The Wide Chasm Priced Into Boston Scientific Stock
Just How Much Risk Is Built Into ISRG Stock? 2026-07-09
Just How Much Risk Is Built Into ISRG Stock?
ABBV Leads Its Peer Group. You Pay For That 2026-07-09
ABBV Leads Its Peer Group. You Pay For That
How Large Does Your Portfolio Need to Be to Generate $12,000 a Month? 2026-07-09
How Large Does Your Portfolio Need to Be to Generate $12,000 a Month? — It works out to $144,000 a year, a little more than twice the U.S. per capita disposable personal income of $68,391 reported for the first quarter of 2026.
Yahoo Finance 2026-07-09
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
Yahoo Finance 2026-07-09
Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?
Yahoo Finance 2026-07-09
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Yahoo Finance 2026-07-09
Jim Cramer Says Johnson & Johnson “Will Have Lots of Good News About Its Myriad Blockbuster Drugs”
Yahoo Finance 2026-07-09
BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board
The Retirement Portfolio That Pays You Without Demanding Constant Attention 2026-07-09
The Retirement Portfolio That Pays You Without Demanding Constant Attention — A $60,000 retirement paycheck sounds like a single target, but a portfolio can produce it in very different ways.
J&J wins FDA approval for dual-energy ablation catheter 2026-07-09
J&J wins FDA approval for dual-energy ablation catheter
Yahoo Finance 2026-07-10
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them. 2026-07-10
5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them.
Yahoo Finance 2026-07-10
Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
What Would It Take to Permanently Cover Long-Term Care Insurance Premiums? 2026-07-10
What Would It Take to Permanently Cover Long-Term Care Insurance Premiums? — A healthy 55-year-old buying meaningful inflation protection can face annual premiums in the low-to-mid thousands, and a 55-year-old couple can easily cross $5,000 combined.
JNJ Stock Keeps Climbing. Should You Climb On? 2026-07-10
JNJ Stock Keeps Climbing. Should You Climb On?
Yahoo Finance 2026-07-10
Jim Cramer on Pfizer: “I Can’t Come Up With Where the Growth Is” — The dividend is safe at 7%.
Yahoo Finance 2026-07-10
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off — Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 11.5% over the past six months, topping the S&P 500 by 4.3 percentage points.
Yahoo Finance 2026-07-10
Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure — Pfizer, traded as NYSE:PFE, enters this news cycle with its stock at $24.25 and a value score of 4, alongside mixed multi-year...
Yahoo Finance 2026-07-10
Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue — DALLAS, July 10, 2026--Dean Omar Branham Shirley, LLP (DOBS), announced today that the Illinois Appellate Court has affirmed a $45 million jury verdict awarded to the family of Theresa Garcia, who developed the deadly disease mesothelioma after decades of using Johnson & Johnson's Baby Powder.
Three Dividend Strategies That Can Produce $7,500 a Month and Which One Comes Out Ahead 2026-07-10
Three Dividend Strategies That Can Produce $7,500 a Month and Which One Comes Out Ahead — Replacing $7,500 a month with dividends is a math problem before it is anything else.
Yahoo Finance 2026-07-10
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults
Yahoo Finance 2026-07-10
Pfizer Poised for Mixed Second Quarter, RBC Says
A Dividend Portfolio That Pays For Your Pets 2026-07-10
A Dividend Portfolio That Pays For Your Pets
Yahoo Finance 2026-07-10
Johnson & Johnson (JNJ) Faces Fresh Talc Risk After $45 Million Verdict Stands — The Illinois Appellate Court upheld a $45 million talc verdict against Johnson & Johnson. For investors following Johnson & Johnson (NYSE: JNJ), this legal outcome arrives while the stock trades at $256.98. The company has recorded a 7.8% return over the past 30 days and...
Yahoo Finance 2026-07-10
Merck (MRK) Stock Sinks As Market Gains: Here's Why — In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.
Yahoo Finance 2026-07-10
Why Verizon, Clorox and More Dividend Stocks Are Flashing a Buy Signal
Yahoo Finance 2026-07-10
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
Jim Cramer recommends buying these 5 stocks 2026-07-10
Jim Cramer recommends buying these 5 stocks
Yahoo Finance 2026-07-10
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout 2026-07-10
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? 2026-07-10
Pfizer's long-acting GLP-1 candidate could disrupt Lilly-Novo duopoly if phase data is positive
The Retirement Budget Most People Build Is Backward 2026-07-11
The Retirement Budget Most People Build Is Backward — Higher yield shrinks the required capital, so the math seduces you toward 8%, 10%, or 12% strategies.
Eli Lilly (LLY) To Share New Kisunla And Alzheimer’s Blood Test Data At AAIC 2026-07-11
Lilly to present long-term Kisunla Alzheimer's data at AAIC — major pipeline readout catalyst
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 2026-07-11
LLY appears on dividend stock screens with attractive yield, suggesting institutional accumulation alongside pipeline optionality
Your Dividend Yield Isn’t Your Income: What You Really Keep After Taxes 2026-07-12
Your Dividend Yield Isn’t Your Income: What You Really Keep After Taxes — Two retirees can both pull $100,000 from $2 million income portfolios and still land in very different places after tax. If one stream is mostly qualified dividends and the other is mostly ordinary income, the first retiree may keep about $79,000 after a 15% federal qualified-dividend rate and 6% state tax.
The Dividend Growth Approach That Builds Bigger Paychecks Every Single Year 2026-07-12
The Dividend Growth Approach That Builds Bigger Paychecks Every Single Year — Ten years ago, a buyer of Lowe’s (NYSE:LOW) could pick up shares near $66 and collect a quarterly dividend that rose to $0.35 later in 2016. Today, the same share pays $1.25 per quarter, and the stock recently traded near $222.
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cli 2026-07-13
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears — SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.
Yahoo Finance 2026-07-13
2 Value Stocks Worth Your Attention and 1 Facing Headwinds
Yahoo Finance 2026-07-13
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account 2026-07-13
Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account — An $80,000 salary is not the same as $80,000 of spendable income. For a single filer in a no-income-tax state, 2026 take-home pay on an $80,000 salary would be about $65,100 before retirement contributions, ... Think You’ll Live on $80,000 a Year?
How Does LLY Stock Reach $2,100? 2026-07-13
How Does LLY Stock Reach $2,100? — At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario.
Yahoo Finance 2026-07-13
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 — INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation pr…
Agenus surges on study pivot; Apnimed lines up an IPO 2026-07-13
Agenus surges on study pivot; Apnimed lines up an IPO
Own Regeneron For Biotech Growth? Incyte Is Making Its Case. 2026-07-13
Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
Yahoo Finance 2026-07-13
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece — Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in GreeceFive-year agreement expected to contribute to revenue and cash-flow visibilityAs a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reachDIABI…
Yahoo Finance 2026-07-13
Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?
JNJ Vs. KO: Which Dividend Stock Is The Better Buy? 2026-07-13
JNJ Vs. KO: Which Dividend Stock Is The Better Buy?
Yahoo Finance 2026-07-13
Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says
Yahoo Finance 2026-07-13
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
Yahoo Finance 2026-07-13
Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?
Yahoo Finance 2026-07-13
Pfizer (PFE) Advances While Market Declines: Some Information for Investors — In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.
This Portfolio Lets You Earn More Than a Lawyer… Without Going to Law School 2026-07-13
This Portfolio Lets You Earn More Than a Lawyer… Without Going to Law School — The median annual wage for lawyers was $151,160 in May 2024, and attorneys in higher-paid roles can clear $200,000 or more.
What It Means To Hold Moderna Stock In A Crash 2026-07-13
What It Means To Hold Moderna Stock In A Crash
Yahoo Finance 2026-07-14
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape
Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen 2026-07-14
Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses 2026-07-14
HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses
Yahoo Finance 2026-07-14
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results
Yahoo Finance 2026-07-14
Johnson & Johnson (JNJ) Stock May Be Reasonable After Talc Verdict Ruling — Johnson & Johnson stock has returned 77.8% over the past five years and now sits at a point where a Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside while the broader valuation checks look much less generous. A 77.8% five year return sets the context for assessing whether today’s price still leaves enough potential reward for the risk involved.
A Dividend Portfolio That Can Cover the Cost of Living in San Francisco 2026-07-14
A Dividend Portfolio That Can Cover the Cost of Living in San Francisco — SmartAsset’s 2026 comfort-salary study estimates that a single adult needs about $134,950 in pretax income to live comfortably in the city, among the highest figures in the country.
Yahoo Finance 2026-07-14
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge — JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.
Yahoo Finance 2026-07-14
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
Yahoo Finance 2026-07-14
Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design — SAN FRANCISCO, July 14, 2026--Chai Discovery, the company engineering AI models to discover new molecules, today announced a $400M Series C fundraise to further accelerate progress.
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug 2026-07-14
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug
The Paid-To-Hold Play On ISRG Stock: A 12% Income 2026-07-14
The Paid-To-Hold Play On ISRG Stock: A 12% Income
What Lilly's Peer-Beating Numbers Cost You 2026-07-14
What Lilly's Peer-Beating Numbers Cost You
This Healthcare Giant Still Checks Every Box for Long-Term Investors 2026-07-14
This Healthcare Giant Still Checks Every Box for Long-Term Investors — Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be.
A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets 2026-07-14
A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets — A $1.4 million nest egg is far above the typical U.S. retirement account balance, but the check it writes each month depends entirely on how the assets are arranged. At a 3.5% yield, the portfolio produces $49,000 a year. At a 10% yield, it produces $140,000.
Here's What to Expect From Pfizer's Next Earnings Report 2026-07-14
Here's What to Expect From Pfizer's Next Earnings Report
ISRG Stock: What Does Its Valuation Imply? 2026-07-14
ISRG Stock: What Does Its Valuation Imply?
Earnings Preview: What To Expect From Merck & Co.'s Report 2026-07-14
Earnings Preview: What To Expect From Merck & Co.'s Report
Yahoo Finance 2026-07-14
Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen — For investors watching Pfizer at a share price of $24.25, this approval adds a fresh development to the oncology...
Yahoo Finance 2026-07-14
Earnings live: Wall Street bank stocks mixed despite profit haul
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill 2026-07-14
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
Yahoo Finance 2026-07-15
Can Dow Jones' Merck Nab $25 Billion With Its Smart Bomb For Cancer?
J&J raises FY26 outlook following positive Q2 2026-07-15
J&J raises FY26 outlook following positive Q2 — Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.
Yahoo Finance 2026-07-15
Johnson & Johnson (JNJ) Tops $100 Billion In Annual Revenue For The First Time — Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices.
Yahoo Finance 2026-07-15
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
Yahoo Finance 2026-07-15
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise? — ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance 2026-07-15
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance — The healthcare company posted adjusted earnings per share of $2.90 for...
Yahoo Finance 2026-07-15
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC
Yahoo Finance 2026-07-15
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ...
Yahoo Finance 2026-07-15
J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies 2026-07-15
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
The Open Questions On ISRG Stock 2026-07-15
The Open Questions On ISRG Stock
Johnson & Johnson Q2 Earnings Call Highlights 2026-07-15
Johnson & Johnson Q2 Earnings Call Highlights
Yahoo Finance 2026-07-15
AM Best Affirms Credit Ratings of Blue Whale Re Ltd.
Best Dividend Stocks to Buy for Dependable Dividend Growth 2026-07-15
Best Dividend Stocks to Buy for Dependable Dividend Growth
Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner 2026-07-15
Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner
Yahoo Finance 2026-07-15
Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment — (NASDAQ:HALO) and assigned a target price of $95.
Yahoo Finance 2026-07-15
Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Yahoo Finance 2026-07-15
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Economic Reports — The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1%, and the actively tra
Yahoo Finance 2026-07-15
Merck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer Use
Celcuity gains FDA approval for closely watched breast cancer drug 2026-07-15
Celcuity gains FDA approval for closely watched breast cancer drug — Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk.
Yahoo Finance 2026-07-15
Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn
SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot 2026-07-16
SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot
MetroLoft Leads $104M Office-to-Residential Bet in FiDi 2026-07-16
MetroLoft Leads $104M Office-to-Residential Bet in FiDi — MetroLoft and Quantum Pacific bought 1 Whitehall St. for $104.5M to convert the FiDi office tower into housing.
Yahoo Finance 2026-07-16
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion — Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion.
Yahoo Finance 2026-07-16
Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
Yahoo Finance 2026-07-16
Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says
Yahoo Finance 2026-07-16
Why Abbott Stock Is Having Its Best Day in 24 Years
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? 2026-07-16
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? — One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Yahoo Finance 2026-07-16
Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat
Yahoo Finance 2026-07-16
FDA approves first-of-its-kind cholesterol pill Lipfendra: What it will cost — The daily medication is expected to be list-priced at $10.50 per pill.
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? 2026-07-16
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? — On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug 2026-07-16
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug — Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.
The Portfolio That Pays All Your Car Repairs For Life 2026-07-16
The Portfolio That Pays All Your Car Repairs For Life
Yahoo Finance 2026-07-16
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
Yahoo Finance 2026-07-16
Merck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise Targets — Merck is back in focus as analysts refine their models, with bullish firms now setting price targets in a US$138 to US$155 range that sit above a refreshed fair value estimate of US$132.78 per share.
Yahoo Finance 2026-07-16
Sector ETFs to Win on Q2 Earnings Growth Potential
Why Is PSNL Stock Up 5% After-Hours? 2026-07-16
Why Is PSNL Stock Up 5% After-Hours?
Yahoo Finance 2026-07-16
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
Why Abbott Stock Is Reimagining Its Future 2026-07-16
Why Abbott Stock Is Reimagining Its Future
What Could Push LLY Stock Higher From Here? 2026-07-16
What Could Push LLY Stock Higher From Here? — These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.
Yahoo Finance 2026-07-16
Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says
Yahoo Finance 2026-07-16
Merck Opens BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe — Darmstadt, Germany, July 16, 2026 (GLOBE NEWSWIRE) -- New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing and GMP-compliant stability studiesStrategic
Yahoo Finance 2026-07-16
Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
Yahoo Finance 2026-07-16
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
Yahoo Finance 2026-07-16
DePuy Synthes Acquires Expanding Innovations™
SPYI Investors: Watch These 2 Macro Factors Before the Next Distribution 2026-07-17
SPYI Investors: Watch These 2 Macro Factors Before the Next Distribution — SPYI's 12% annualized payout looks generous until you check what two converging macro forces are quietly doing to the premium engine that funds it.
Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income? 2026-07-17
Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income? — It is also more than the $3,208 average monthly Social Security benefit SSA estimates for an aged couple, both receiving benefits, in January 2026. A portfolio producing another $4,000 a month can materially ...
Yahoo Finance 2026-07-17
Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years
Yahoo Finance 2026-07-17
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Yahoo Finance 2026-07-17
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
Yahoo Finance 2026-07-17
Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.
Boomers Swear by These High-Yield 5% and More Kings They Can Buy and Hold Forever 2026-07-17
Boomers Swear by These High-Yield 5% and More Kings They Can Buy and Hold Forever — These five high-yield stocks earning 6% or more are winning over Boomers who refuse to let rising prices eat their savings alive.
Can Abbott Stock Deliver on Its Second-Half Growth Promise? 2026-07-17
Can Abbott Stock Deliver on Its Second-Half Growth Promise?
The Real Question Buried Inside Merck Stock's Premium Price 2026-07-17
The Real Question Buried Inside Merck Stock's Premium Price
DGRO’s December Rebalance Could Reshape Healthcare Exposure: Here’s What to Watch 2026-07-17
DGRO’s December Rebalance Could Reshape Healthcare Exposure: Here’s What to Watch
VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way 2026-07-17
VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way — With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.
Yahoo Finance 2026-07-17
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
Yahoo Finance 2026-07-17
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances 2026-07-17
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
Abbott Just Showed Its Growth Engine Has More Than One Cylinder 2026-07-17
Abbott Just Showed Its Growth Engine Has More Than One Cylinder
Yahoo Finance 2026-07-17
New Cholesterol Pill, Earnings Growth Boost Merck Shares — (MRK) rise 3,453% since 1990 thanks to institutional investors.
GSK shelves cough drug acquired in $2B deal 2026-07-17
GSK shelves cough drug acquired in $2B deal
If Volatility Stays Low, Here’s What Happens to DIVO’s Monthly Income 2026-07-18
If Volatility Stays Low, Here’s What Happens to DIVO’s Monthly Income
The Portfolio That Gives You a $2,000 Raise Every Year 2026-07-18
The Portfolio That Gives You a $2,000 Raise Every Year
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the 2026-07-18
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? — Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.
The Portfolio That Lets You Cruise Through the News, Unbothered 2026-07-18
The Portfolio That Lets You Cruise Through the News, Unbothered
Here’s the Funding It Takes to Keep Learning Forever 2026-07-18
Here’s the Funding It Takes to Keep Learning Forever
The Portfolio That Lets You Ignore Inflation 2026-07-19
The Portfolio That Lets You Ignore Inflation
Yahoo Finance 2026-07-19
Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug — Merck, trading around $127.5, is adding Lipfendra to its portfolio at a time when NYSE:MRK has posted a 64.8% return over the past year and 92.2% over five years.
Would You Rather Earn $55,000 Today or $110,000 in 20 Years? 2026-07-19
Would You Rather Earn $55,000 Today or $110,000 in 20 Years? — A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it.
Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now 2026-07-19
Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now
Yahoo Finance 2026-07-19
Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device — For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2.
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report? 2026-07-19
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?
Yahoo Finance 2026-07-20
Bear of the Day: J&J Snack Foods (JJSF)
Yahoo Finance 2026-07-20
What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.
Yahoo Finance 2026-07-20
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive — Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday.
Yahoo Finance 2026-07-20
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
Yahoo Finance 2026-07-20
1 Stock Under $50 to Target This Week and 2 We Question — Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
Yahoo Finance 2026-07-20
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Yahoo Finance 2026-07-20
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
Yahoo Finance 2026-07-20
Beat the Market the Zacks Way: Liquidia, BILL, Colgate-Palmolive in Focus
The Robot Maker's Paradox 2026-07-20
The Robot Maker's Paradox — The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.
Reading Between The Lines Of JNJ Stock's Latest Call 2026-07-20
Reading Between The Lines Of JNJ Stock's Latest Call
What's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth? 2026-07-20
What's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?
Eli Lilly Stock And The Price Of Confidence 2026-07-20
Eli Lilly Stock And The Price Of Confidence
Yahoo Finance 2026-07-20
Merck (MRK) Declines More Than Market: Some Information for Investors — Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.
Yahoo Finance 2026-07-20
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know — In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.
Yahoo Finance 2026-07-21
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
Yahoo Finance 2026-07-21
HALO Inks Deal With INCY to Support Cancer Therapy Development
70 Dividend Aristocrats Face Their Mid-2026 Test: NOBL’s 2% Yield Under Pressure 2026-07-21
70 Dividend Aristocrats Face Their Mid-2026 Test: NOBL’s 2% Yield Under Pressure
Yahoo Finance 2026-07-21
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Yahoo Finance 2026-07-21
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Yahoo Finance 2026-07-21
MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
Eli Lilly Stock And The Price Of Confidence 2026-07-21
Eli Lilly Stock And The Price Of Confidence
Why BSX Stock Hands You So Much Cash Right Now 2026-07-21
Why BSX Stock Hands You So Much Cash Right Now
ISRG Stock: The Math Hidden In Its Price 2026-07-21
ISRG Stock: The Math Hidden In Its Price — At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part.
Yahoo Finance 2026-07-21
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)
AbbVie Stock Zigs When The Market Zags 2026-07-21
AbbVie Stock Zigs When The Market Zags
Yahoo Finance 2026-07-21
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win — Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Yahoo Finance 2026-07-21
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsi
Yahoo Finance 2026-07-21
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Yahoo Finance 2026-07-21
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatm
Yahoo Finance 2026-07-22
Johnson & Johnson (JNJ) Raised Its Dividend, Where Does Fair Value Sit? — Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income focused investors with fresh information on the stock’s current payout profile and upcoming key dates.
Yahoo Finance 2026-07-22
Rockwell Medical Advances Quality and Regulatory Leadership
Yahoo Finance 2026-07-22
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026 — The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year.
Yahoo Finance 2026-07-22
Trump Takes Another Swing at Drug Industry in Made-in-USA Push — (Bloomberg) -- President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began.
LLY Has Momentum. The Question Is The Price 2026-07-22
LLY Has Momentum. The Question Is The Price
Yahoo Finance 2026-07-22
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Yahoo Finance 2026-07-22
Connecticut Innovations Generates Record $66.5 Million in Proceeds in FY2026 — Connecticut Innovations (CI), the state's strategic venture capital arm, today announced a record-breaking fiscal year, generating $66.5 million in cash proceeds from a series of landmark portfolio exits and a combined $76.1 million from all investment activities.
Yahoo Finance 2026-07-22
Can LQDA's Differentiated PAH Strategy Drive Long-Term Growth?
Yahoo Finance 2026-07-22
Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?
Yahoo Finance 2026-07-22
Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies
Yahoo Finance 2026-07-22
J&J enters US robotic surgery market after device gets marketing authorization
Yahoo Finance 2026-07-22
Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside — The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...
J&J MedTech jumps into surgical robot game as OTTAVA secures FDA nod 2026-07-22
J&J MedTech jumps into surgical robot game as OTTAVA secures FDA nod
Yahoo Finance 2026-07-22
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?
Yahoo Finance 2026-07-22
ISRG Growth Story Hinges on Da Vinci 5, Ion and Recurring Revenue
Yahoo Finance 2026-07-22
ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure
Yahoo Finance 2026-07-22
Is ISRG Stock Worth Buying as Growth Stays Strong but Risks Rise
Yahoo Finance 2026-07-22
Are You Looking for a High-Growth Dividend Stock?
Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today 2026-07-22
Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today
Yahoo Finance 2026-07-22
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive 2026-07-22
J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive
Why Did PEGA, ISRG, MCD Stocks Plunge To 52-Week Lows Today? 2026-07-23
Why Did PEGA, ISRG, MCD Stocks Plunge To 52-Week Lows Today?
Yahoo Finance 2026-07-23
Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?
Yahoo Finance 2026-07-23
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline — Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]
Organon & Co. Shareholders Clear Sun Pharma Merger Deal 2026-07-23
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Yahoo Finance 2026-07-23
Cell Culture Market Analysis by Consumables, Vessels, Equipment, Application, and Competition - Global Forecast to 2031
Yahoo Finance 2026-07-23
In Vitro Toxicology Testing Market to Exceed $20.97 Billion by 2031 as Non-Animal Testing & AI Adoption Accelerate - Analysis by Product, Toxicity Endpoints & Type, Technology, Method, Service, Region
Yahoo Finance 2026-07-23
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
Yahoo Finance 2026-07-23
Will GSK's Specialty Medicines Boost Q2 Revenue Growth?
Yahoo Finance 2026-07-23
The 5th Annual Connected Worker Manufacturing Summit Returns Bigger Than Ever with Its Largest Speaker Faculty, Expo Hall and Industry Audience to Date
Yahoo Finance 2026-07-23
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
Yahoo Finance 2026-07-23
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
Yahoo Finance 2026-07-23
PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use
Yahoo Finance 2026-07-23
Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer
Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts 2026-07-23
Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts
J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be 2026-07-23
J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.
Yahoo Finance 2026-07-24
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
Yahoo Finance 2026-07-24
J&J's Innovative Medicine Unit Proves Its Resilience in Q2
Yahoo Finance 2026-07-24
FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System
Intuitive Surgical Stock Is On Sale, But Is The Growth Story Changing? 2026-07-24
Intuitive Surgical Stock Is On Sale, But Is The Growth Story Changing?
3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives 2026-07-24
3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
Yahoo Finance 2026-07-24
Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse
Yahoo Finance 2026-07-24
Par Health Launches First and Only Generic Version of Janumet® XR (sitagliptin and metformin HCl extended-release) Tablets in the United States
Yahoo Finance 2026-07-24
Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher
Yahoo Finance 2026-07-24
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma 2026-07-24
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
Yahoo Finance 2026-07-24
Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma
How Much Do You Need Invested to Match the Maximum Social Security Benefit With Dividends? 2026-07-24
How Much Do You Need Invested to Match the Maximum Social Security Benefit With Dividends?
Yahoo Finance 2026-07-24
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
Johnson & Johnson Is Becoming A Narrower Company Than You Bought 2026-07-25
Johnson & Johnson Is Becoming A Narrower Company Than You Bought
The $2 Million Retirement Mistake: Confusing Yield With Income You Can Actually Spend 2026-07-25
The $2 Million Retirement Mistake: Confusing Yield With Income You Can Actually Spend — A $2 million retirement portfolio can generate wildly different income streams depending on where you put it, and choosing the wrong tier does not just leave money on the table.
Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75? 2026-07-25
Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75?
A $550,000 Portfolio That Quietly Pays a 62-Year-Old $3,400 a Month Until Social Security Kicks In 2026-07-26
A $550,000 Portfolio That Quietly Pays a 62-Year-Old $3,400 a Month Until Social Security Kicks In
How to Build $4,000 a Month in Dividend Income Without Selling a Single Share 2026-07-26
How to Build $4,000 a Month in Dividend Income Without Selling a Single Share — Generating $48,000 a year in dividends sounds like a retirement fantasy until you see how the math actually splits across three very different yield strategies, each demanding a radically different amount of starting capital and carrying its own hidden cost.
Yahoo Finance 2026-07-27
Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative?
Johnson & Johnson Now Leads Its Pitch With An Oncology Bet 2026-07-27
Johnson & Johnson Now Leads Its Pitch With An Oncology Bet
Yahoo Finance 2026-07-27
President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling — The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]
Yahoo Finance 2026-07-27
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson
Yahoo Finance 2026-07-27
Merck (MRK) Is Up 5.4% After Expanding HIV PrEP Access And Launching Oral Cholesterol Drug
Yahoo Finance 2026-07-27
Scribe’s Genetic Editing Aims to Prevent Heart Attacks — Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday.
Yahoo Finance 2026-07-27
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
The Engine Behind ABBV Stock Has Real Parts 2026-07-27
The Engine Behind ABBV Stock Has Real Parts
Yahoo Finance 2026-07-27
UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch
Yahoo Finance 2026-07-27
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips 2026-07-27
Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips
JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation 2026-07-27
JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation
Yahoo Finance 2026-07-27
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation — NEW BRUNSWICK, N.J., July 27, 2026--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remain…
Yahoo Finance 2026-07-27
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial
Yahoo Finance 2026-07-27
This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026 — LGND stock has risen more than 56.5% so far in 2026.
Yahoo Finance 2026-07-27
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
Yahoo Finance 2026-07-27
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Yahoo Finance 2026-07-27
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
Yahoo Finance 2026-07-27
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead — IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
Why Chasing a 9% Yield Could Cost You $200,000 in Retirement Income 2026-07-28
Why Chasing a 9% Yield Could Cost You $200,000 in Retirement Income — Two investors with the same $600,000 can end up hundreds of thousands of dollars apart depending on one number.
Yahoo Finance 2026-07-28
Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer Claims — Johnson & Johnson (JNJ) has agreed to commit up to $5.5 billion to settle about 76,000 lawsuits that
Yahoo Finance 2026-07-28
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
Johnson & Johnson offers $5.5 billion to settle talc lawsuits 2026-07-28
Johnson & Johnson offers $5.5 billion to settle talc lawsuits — Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.
Yahoo Finance 2026-07-28
OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ...
Yahoo Finance 2026-07-28
J&J offers $5.5bn to settle baby powder lawsuits — Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma.
Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation 2026-07-28
Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation — Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with the company committing up to $5.5 billion to settle the remaining claims.
Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuits 2026-07-28
Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuits — Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.
Yahoo Finance 2026-07-28
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Yahoo Finance 2026-07-28
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Yahoo Finance 2026-07-28
Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline
Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion 2026-07-28
Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion — The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect
Yahoo Finance 2026-07-28
Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight — Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least 95% of remaining claimants participating.
Yahoo Finance 2026-07-28
As AI Reshapes Cybersecurity, EWF 2026 Brings Together Industry Leaders to Deliver Practical Solutions
A $1.2 Million Portfolio That Pays $7,000 a Month and Stays Below the IRMAA Surcharge Line 2026-07-28
A $1.2 Million Portfolio That Pays $7,000 a Month and Stays Below the IRMAA Surcharge Line — Generating $7,000 a month in retirement sounds like a math problem, but for Medicare-eligible investors it's also a tax trap where chasing a higher yield can quietly trigger surcharges that claw back the gains.
Does Eli Lilly Stock Actually Diversify Your Portfolio? 2026-07-28
Does Eli Lilly Stock Actually Diversify Your Portfolio?
Yahoo Finance 2026-07-28
Martin Madaus Elected to Haemonetics Board of Directors
3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st 2026-07-28
3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st
Yahoo Finance 2026-07-28
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits 2026-07-28
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits — Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.
Yahoo Finance 2026-07-28
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing — In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.
Yahoo Finance 2026-07-28
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
Yahoo Finance 2026-07-28
Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026
Johnson & Johnson offers £4.1bn to settle talcum powder cancer claims 2026-07-28
Johnson & Johnson offers £4.1bn to settle talcum powder cancer claims — Johnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer.
Yahoo Finance 2026-07-28
Johnson & Johnson reaches $5.5 billion baby powder settlement — STORY: :: New York / July 27, 2026 :: Dietrich Knauth, Legal Reporter "After years of litigation, about 70,000 court cases, and three bankruptcies, Johnson& Johnson has agreed to a $5.5 billion talc settlement.
Yahoo Finance 2026-07-29
Merck Announces Fourth-Quarter 2026 Dividend
Yahoo Finance 2026-07-29
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
Yahoo Finance 2026-07-29
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
The Best House On The Block Costs The Most: ISRG 2026-07-29
The Best House On The Block Costs The Most: ISRG
5 High-Yielding Dividend Stocks for Retirees to Buy and Hold Forever 2026-07-29
5 High-Yielding Dividend Stocks for Retirees to Buy and Hold Forever
Yahoo Finance 2026-07-29
Freehand Raises $75M to Scale AI Teams Managing Supply Chain Spend for Fortune 500 Companies
Yahoo Finance 2026-07-29
Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
Yahoo Finance 2026-07-29
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation — NEW BRUNSWICK, N.J., July 29, 2026--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash.
Yahoo Finance 2026-07-29
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
This $3 Million Portfolio Pays $18,000 a Month From Three Income Buckets 2026-07-29
This $3 Million Portfolio Pays $18,000 a Month From Three Income Buckets — A $3 million portfolio sounds like enough to retire on, but the math gets uncomfortable fast when you need $18,000 a month and a single income strategy quietly destroys the principal it was supposed to protect.
The Real Price of AbbVie Stock Is Cheaper Than You Think 2026-07-29
The Real Price of AbbVie Stock Is Cheaper Than You Think
Yahoo Finance 2026-07-29
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
Yahoo Finance 2026-07-29
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
Yahoo Finance 2026-07-29
Merck (MRK) Stock Moves -1.11%: What You Should Know — In the most recent trading session, Merck (MRK) closed at $130.36, indicating a -1.11% shift from the previous trading day.
Yahoo Finance 2026-07-29
Boston Scientific Cuts Outlook Amid Weak Demand for Watchman Heart Device
Yahoo Finance 2026-07-29
Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth 2026-07-29
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth
Yahoo Finance 2026-07-30
Pfizer (PFE) Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season
Yahoo Finance 2026-07-30
Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement — Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...
EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals 2026-07-30
EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals
Yahoo Finance 2026-07-30
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | Delve
Yahoo Finance 2026-07-30
Bristol Myers Stock Rises. Why the Drugmaker Is Lifting Its Earnings Guidance.
Yahoo Finance 2026-07-30
Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Yahoo Finance 2026-07-30
Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS
Yahoo Finance 2026-07-30
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head
Yahoo Finance 2026-07-30
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Yahoo Finance 2026-07-30
Sector Update: Healthcare Stocks Decline Late Afternoon — Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and
Yahoo Finance 2026-07-30
Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
Yahoo Finance 2026-07-30
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
Alnylam plunges as earnings deliver ‘one-two punch’ 2026-07-30
Alnylam plunges as earnings deliver ‘one-two punch’ — The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat 2026-07-30
Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat — Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates
Yahoo Finance 2026-07-30
Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma
Yahoo Finance 2026-07-30
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? 2026-07-31
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo Finance 2026-07-31
Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Yahoo Finance 2026-07-31
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?
Yahoo Finance 2026-07-31
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
Yahoo Finance 2026-07-31
Amgen Q2 Earnings Preview: Will the Beat Streak Continue?
Yahoo Finance 2026-07-31
Moderna Stock Has Doubled This Year. Can Earnings Keep the Rally Alive?
Yahoo Finance 2026-07-31
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
Yahoo Finance 2026-07-31
AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition
The Signs Before Eli Lilly Stock Surged Were All On The Record 2026-07-31
The Signs Before Eli Lilly Stock Surged Were All On The Record
LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15% 2026-07-31
LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15%
Is Wall Street Bullish or Bearish on Johnson & Johnson Stock? 2026-07-31
Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?
Yahoo Finance 2026-07-31
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
No Options, No Leverage, No Gimmicks: 3 Dividend ETFs Paying Over 4 Percent the Old-Fashioned Way 2026-07-31
No Options, No Leverage, No Gimmicks: 3 Dividend ETFs Paying Over 4 Percent the Old-Fashioned Way
J&J’s biotech progress could punish its 2027 profit 2026-08-01
J&J’s biotech progress could punish its 2027 profit
Yahoo Finance 2026-08-01
Merck (MRK) Plans Early HIV Pill Licensing Across 129 Countries
Yahoo Finance 2026-08-01
Pfizer (PFE) Stock Looks Reasonable Based On Today’s Broader Checks
Yahoo Finance 2026-08-01
Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases
Yahoo Finance 2026-08-02
This Surgical Robot Could Transform the Operating Room
Yahoo Finance 2026-08-03
Pfizer (PFE) Q2 Earnings: What To Expect
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be 2026-08-03
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
Yahoo Finance 2026-08-03
Lipocine Appoints Michael J. Grissinger to Board of Directors
Yahoo Finance 2026-08-03
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Yahoo Finance 2026-08-03
What To Expect From Merck’s (MRK) Q2 Earnings
Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield 2026-08-03
Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?
Yahoo Finance 2026-08-03
Johnson & Johnson (JNJ) Gets FDA Nod For OTTAVA As It Enters Surgical Robotics
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity 2026-08-03
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity
Yahoo Finance 2026-08-03
Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
Yahoo Finance 2026-08-03
Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone
Yahoo Finance 2026-08-03
Stocks mixed as AstraZeneca merger talk dents FTSE 100
Yahoo Finance 2026-08-03
J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes
Yahoo Finance 2026-08-03
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off 2026-08-03
$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off
Yahoo Finance 2026-08-03
Agilent Technologies (A) Expands Its Oncology Diagnostics Reach—Can Growth Keep Up?
AbbVie's Growth Now Leans On A Single Molecule 2026-08-03
AbbVie's Growth Now Leans On A Single Molecule
Johnson & Johnson’s OTTAVA Robotic Surgery System Targets Long-Term Growth 2026-08-03
Johnson & Johnson’s OTTAVA Robotic Surgery System Targets Long-Term Growth
Yahoo Finance 2026-08-03
Are Medical Stocks Lagging Avantor (AVTR) This Year?
Yahoo Finance 2026-08-03
Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?
Medicus Pharma CMO to lead Antev's Teverelix clinical programme 2026-08-03
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Medicare Now Takes $202.90 a Month Straight From Your Social Security Check. These 3 ETFs Pay It Bac 2026-08-04
Medicare Now Takes $202.90 a Month Straight From Your Social Security Check. These 3 ETFs Pay It Back
Yahoo Finance 2026-08-04
The Merck Product That Absolutely Demolished Wall Street's Forecasts
Yahoo Finance 2026-08-04
Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat
Yahoo Finance 2026-08-04
NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off
Yahoo Finance 2026-08-04
Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.
Yahoo Finance 2026-08-04
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
Yahoo Finance 2026-08-04
Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue
Merck Shares Advance After Strong Second-Quarter Earnings and Higher Revenue Outlook 2026-08-04
Merck Shares Advance After Strong Second-Quarter Earnings and Higher Revenue Outlook
WSJ 2026-08-04
Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs
Yahoo Finance 2026-08-04
Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says
Yahoo Finance 2026-08-04
MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised
Yahoo Finance 2026-08-04
Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
Pfizer repels Covid-19 sales tumble to raise 2026 guidance 2026-08-04
Pfizer repels Covid-19 sales tumble to raise 2026 guidance
Yahoo Finance 2026-08-04
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
Yahoo Finance 2026-08-04
PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut
Yahoo Finance 2026-08-04
Pfizer's Recovery Story Is Starting to Look More Durable
Yahoo Finance 2026-08-04
Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats
How Much Do You Really Need Invested to Replace a $100,000 Salary With Dividends? 2026-08-04
How Much Do You Really Need Invested to Replace a $100,000 Salary With Dividends?
Pfizer Inc. Q2 2026 Earnings Call Summary 2026-08-04
Pfizer Inc. Q2 2026 Earnings Call Summary
Yahoo Finance 2026-08-04
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story
Yahoo Finance 2026-08-04
Merck & Co Inc (MRK) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...
Yahoo Finance 2026-08-04
Pfizer Earnings Reveal New Engine Beyond Covid
Yahoo Finance 2026-08-04
Sector Update: Healthcare Stocks Softer Late Afternoon
Pfizer raises revenue outlook after quarterly earnings top estimates 2026-08-04
Pfizer raises revenue outlook after quarterly earnings top estimates
Yahoo Finance 2026-08-04
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
Trefis 2026-08-05
Why PFE Stock Hands You So Much Cash Right Now
24/7 Wall St. 2026-08-05
The Dividend Income Illusion: Why Your 8% Yield Is Really Paying You 5% — An 8% yield looks like a shortcut to $80,000 a year without selling a single share, but the brokerage account tells a different story than the headline number does.
Yahoo Finance 2026-08-05
Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance — Royalty Pharma PLC (RPRX) reports 14% total receipts growth and raises full-year 2026 guidance for the second consecutive quarter.
Yahoo Finance 2026-08-05
Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ... — Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.
Yahoo Finance 2026-08-05
LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance Raised
Yahoo Finance 2026-08-05
Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?
Yahoo Finance 2026-08-05
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
Yahoo Finance 2026-08-05
Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedoti
Yahoo Finance 2026-08-05
MRK Q2 Earnings Call Puts Pipeline Progress in Focus
Yahoo Finance 2026-08-05
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease 2026-08-05
MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease
Merck & Co., Inc. Q2 Earnings Call Highlights 2026-08-05
Merck & Co., Inc. Q2 Earnings Call Highlights — (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield.
24/7 Wall St. 2026-08-05
Dividends vs. an Annuity: Which Turns $675,000 Into More Monthly Income for Life? — Annuity payouts are the most competitive they have been in years, which makes the timing of this comparison unusually consequential for anyone sitting on a $675,000 nest egg and trying to decide which structure actually puts more money in their pocket for life.
Yahoo Finance 2026-08-05
Johnson & Johnson (JNJ) Could Be 10% Overvalued Following Leadership Change — Johnson & Johnson’s share price has had a strong run in 2026, with a year to date share price return of 22.95% and a 90 day share price return of 13.49%, while the 1 year total shareholder return of 53.04%...
Yahoo Finance 2026-08-06
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...
Stocktwits 2026-08-06
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals — Novavax raised its full-year 2026 adjusted total revenue outlook to $235–$275 million from $230–$270 million.
24/7 Wall St. 2026-08-06
How to Build $8,500 a Month in Dividend Income Without Selling a Single Share
24/7 Wall St. 2026-08-06
Johnson & Johnson Is Spending $1 Billion to Make More Contact Lenses. Medicare Covers Them in Only One Narrow Situation.
Yahoo Finance 2026-08-06
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
24/7 Wall St. 2026-08-06
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
Yahoo Finance 2026-08-06
Why This Biotech Dealmaker — Tied To Merck, Travere — Charged Higher
Yahoo Finance 2026-08-06
ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?
Yahoo Finance 2026-08-06
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
Merck KGaA Q2 Earnings Call Highlights 2026-08-06
Merck KGaA Q2 Earnings Call Highlights — Group net sales rose 3.4% year over year to €5.434 billion.
Moby 2026-08-06
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data 2026-08-06
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
24/7 Wall St. 2026-08-06
5 Solid Dividend Stocks to Buy in August — With the 10-year Treasury yield near 4.70%, dividend stocks face a real test of relevance, and only a handful of names have the streak length and earnings power to still make the cut right now.
24/7 Wall St. 2026-08-07
The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer? — A $1.25 million nest egg can fund a very different retirement depending on one number: your withdrawal yield.
Yahoo Finance 2026-08-07
Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits — Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits.
Trefis 2026-08-07
The Two Divergent Paths Priced Into Eli Lilly Stock
Yahoo Finance 2026-08-07
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Yahoo Finance 2026-08-07
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
Yahoo Finance 2026-08-07
Johnson & Johnson (JNJ) Could Be a Great Choice
Yahoo Finance 2026-08-07
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake — Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
Yahoo Finance 2026-08-07
Merck (MRK) Could Be 3% Undervalued On Raised Outlook And Key Drug Approvals — Merck’s share price has moved to US$128.37 after a strong run, with a 90 day share price return of 15.25% and a 1 year total shareholder return of 65.06%, suggesting momentum has been building as approvals, trial readouts and raised...
Yahoo Finance 2026-08-07
Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players — The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding at a compound annual growth rate of approximately 7% between 2025 and 2030.
Yahoo Finance 2026-08-07
Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More
Yahoo Finance 2026-08-07
This Contact Lens Stock Looks Ready to Rally
Yahoo Finance 2026-08-07
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off 2026-08-07
For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off
24/7 Wall St. 2026-08-08
How Much Do You Need Invested to Out-Earn the Average Social Security Check With Dividends?
Yahoo Finance 2026-08-08
Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed — In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations.
24/7 Wall St. 2026-08-08
The Portfolio Blueprint for Building $50,000 a Month in Dividend Income — Chasing a $50,000 monthly dividend stream sounds like a math problem, but the yield you pick determines whether your portfolio funds four decades of freedom or quietly cannibalizes itself while the checks keep arriving.
24/7 Wall St. 2026-08-09
How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62 — A $425,000 nest egg can generate wildly different monthly paychecks depending on where you put it, but chasing the biggest number often destroys the very asset you need to last through your 70s.
Trefis 2026-08-10
What Analysts Really Pressed LLY On This Quarter
Yahoo Finance 2026-08-10
Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings? — Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts’ average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85.
24/7 Wall St. 2026-08-10
The IRS Just Gave 65-Year-Olds a New $6,000 Deduction. These 3 ETFs Turn the Tax Break Into Monthly Income
TheStreet 2026-08-10
140-year-old Dividend King eyes bold update to unlock new growth
Trefis 2026-08-10
Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company
Yahoo Finance 2026-08-10
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Trefis 2026-08-10
Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection
Yahoo Finance 2026-08-10
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Yahoo Finance 2026-08-10
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Yahoo Finance 2026-08-10
ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?
Yahoo Finance 2026-08-10
Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
Yahoo Finance 2026-08-10
ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers
Trefis 2026-08-11
JNJ Keeps Climbing. Should You Climb On?
Trefis 2026-08-11
$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off
24/7 Wall St. 2026-08-11
This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It’s Up 18.5% in 2026
24/7 Wall St. 2026-08-11
Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold? — Johnson & Johnson has surged more than 50% in a year and now sits within striking distance of its 52-week high, but a closer look at the valuation, insider activity, and pipeline pressures raises a pointed question about who actually wins from here.
Yahoo Finance 2026-08-11
Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children
Pfizer agrees to $44M Chantix settlement. See if you qualify 2026-08-11
Pfizer agrees to $44M Chantix settlement. See if you qualify — Pfizer agreed to a $44 million Chantix settlement.
The Motley Fool 2026-08-11
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? — Both of these stocks pay more than double the S&P 500 average of 1.1%.
Yahoo Finance 2026-08-11
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
24/7 Wall St. 2026-08-11
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Yahoo Finance 2026-08-11
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
The Motley Fool 2026-08-11
Merck (MRK) Q2 2026 Earnings Call Transcript — Oncology and animal health drove $16.6B revenue growth amid upcoming patent expirations.
The Motley Fool 2026-08-11
Pfizer (PFE) Q2 2026 Earnings Call Transcript — Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.
24/7 Wall St. 2026-08-11
Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run
Yahoo Finance 2026-08-11
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?
Yahoo Finance 2026-08-11
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
Yahoo Finance 2026-08-11
The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"
24/7 Wall St. 2026-08-11
How a 65-Year-Old Turned a $950,000 401(k) Rollover Into a $4,500 Monthly Paycheck Without Buying an Annuity — Pulling $54,000 a year from a $950,000 rollover IRA sounds like a math problem, but the real trap is hidden in the yield tier you choose and what it quietly does to your principal over time.
Yahoo Finance 2026-08-11
What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders — In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies.
Yahoo Finance 2026-08-12
5 Insightful Analyst Questions From Merck’s Q2 Earnings Call
Trefis 2026-08-12
The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income
Trefis 2026-08-12
How ABBV Stock Moved Away From Its Peer Group
Trefis 2026-08-12
Amgen Stock And The Price Of A Promise
Yahoo Finance 2026-08-12
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines? — Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
24/7 Wall St. 2026-08-12
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
Trefis 2026-08-12
Two Years Of Growth Barely Change What You Pay For Intuitive Surgical
Yahoo Finance 2026-08-12
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
Yahoo Finance 2026-08-12
Intuitive Surgical: Oppenheimer now bullish, sees competition being "crowded out" — Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of "Crowding Out Competitors" is strategically smart.
24/7 Wall St. 2026-08-12
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Yahoo Finance 2026-08-12
Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall
24/7 Wall St. 2026-08-12
The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More — Five long-established index members still pay 6% or more, and all carry Buy ratings from top Wall Street analysts.
Yahoo Finance 2026-08-12
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Yahoo Finance 2026-08-12
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update — Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle…
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs 2026-08-12
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs
Yahoo Finance 2026-08-12
Pfizer (PFE) Agreed To A $44 Million Chantix Settlement — Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures.
Yahoo Finance 2026-08-13
Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief? — The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050.
Yahoo Finance 2026-08-13
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Trefis 2026-08-13
How Much More Can Boston Scientific Stock Move After Losing Half Its Value?
24/7 Wall St. 2026-08-13
How a 64-Year-Old Turned an $880,000 401(k) Rollover Into a $5,200 Monthly Paycheck Without Buying an Annuity — Rolling $880,000 into a self-directed IRA sounds like a clean break from the 9-to-5, but generating $5,200 a month from that balance forces a choice between safety and survival that most retirement calculators never show you.
Yahoo Finance 2026-08-13
Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress — Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85.
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money 2026-08-13
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Valneva Q2 Earnings Call Highlights 2026-08-13
Valneva Q2 Earnings Call Highlights
Trefis 2026-08-13
The Sharpest Exchanges From ABBV's Earnings Call
Yahoo Finance 2026-08-13
How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story — In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion.
Yahoo Finance 2026-08-13
Can Keytruda Sustain Merck's Growth in the Second Half of 2026?
Moby 2026-08-13
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance 2026-08-13
Pfizer CEO Buys $1 Million of Stock — Albert Bourla adds 38,000 shares.
Yahoo Finance 2026-08-13
This Healthcare Services Stock Has 37% Upside — Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.
Yahoo Finance 2026-08-13
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
Yahoo Finance 2026-08-14
This Dividend Aristocrat Posted Record Quarterly Results — Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%.
Trefis 2026-08-14
AbbVie Defends Its Turf, But Leaves One Big Question Open
Yahoo Finance 2026-08-14
Can BMY's First CELMoD Approval Support Its Growth Strategy?
Yahoo Finance 2026-08-14
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
Stocktwits 2026-08-14
Why Did VALN Stock Surge 24% Today?
Yahoo Finance 2026-08-14
Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report?
Yahoo Finance 2026-08-14
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene 2026-08-14
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
24/7 Wall St. 2026-08-14
3 High-Yield Dividend Stocks Under $30 to Buy in August — Three dividend stocks near or under $30 caught our attention this August, and at least one of them carries a yield so high it comes with a built-in warning label worth reading before you buy.
24/7 Wall St. 2026-08-14
How a Retired Couple Collects $11,500 a Month and Never Pays an IRMAA Surcharge
Yahoo Finance 2026-08-14
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Yahoo Finance 2026-08-14
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
24/7 Wall St. 2026-08-16
5 Dividend Aristocrats to Buy for Lifelong Income in August
Yahoo Finance 2026-08-16
2 Large-Cap Stocks for Long-Term Investors and 1 We Avoid
Trefis 2026-08-17
Why Isn't Eli Lilly Stock Trading At The Top Of Its Peer Group?
Yahoo Finance 2026-08-17
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Yahoo Finance 2026-08-17
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies — Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec
Yahoo Finance 2026-08-17
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
24/7 Wall St. 2026-08-17
How Much Do You Really Need Invested to Replace a $75,000 Salary With Dividends?
Yahoo Finance 2026-08-17
Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca — With approximately 15 ADCs approved worldwide, over 200 candidates in clinical trials, and more than 400 in development, this study analyzes 3,761 patent families to ma
Yahoo Finance 2026-08-17
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer
Yahoo Finance 2026-08-18
Johnson & Johnson Stock Jumps 3% as Healthcare Rotation Lifts Shares — J&J raises 2026 outlook after second-quarter sales rise 6.6% to $25.31 billion.
Yahoo Finance 2026-08-18
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Yahoo Finance 2026-08-18
Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows
Yahoo Finance 2026-08-18
Nike Stock Hits Lowest Level Since 2014 as Turnaround Drags On — Nike stock has fallen 38% in 2026 as the sportswear giant’s turnaround drags on.
Yahoo Finance 2026-08-18
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
Yahoo Finance 2026-08-18
Johnson & Johnson (JNJ) Wins FDA Clearance For AI Powered MONARCH QUEST 3
24/7 Wall St. 2026-08-18
Billionaire Bruce Berkowitz Reveals 76% Of Fairholme Capital Is in Just 1 Stock
Yahoo Finance 2026-08-18
Michael Burry is Bullish on This Beaten-Down Healthcare Stock. Time to Buy? — The stock is down about 40% so far this year. Zoetis has dropped more than 70% from its 2021 […]
Yahoo Finance 2026-08-18
J&J's New Growth Powerhouses: Immunology and Neuroscience
Yahoo Finance 2026-08-18
Valeris Welcomes Patient Services Veteran Lauren Cole to Lead Commercial Strategy
Yahoo Finance 2026-08-18
Why Colgate-Palmolive Remains an Overlooked Dividend King
24/7 Wall St. 2026-08-18
5 Dependable Dividend Stocks to Buy in August
The Motley Fool 2026-08-18
Warren Buffett and Greg Abel Keep Overlooking This Stock -- but It's One of the Most Berkshire-Ready Picks on the Market
Yahoo Finance 2026-08-18
CONMED (CNMD) Shares Moved, What Is Behind The Fresh Attention? — CONMED’s share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%.
24/7 Wall St. 2026-08-18
How to Build $17,500 a Month in Dividend Income From Three Income Buckets — Generating $210,000 a year in dividends sounds impossible until you break the portfolio into three distinct yield buckets, each with its own risk profile and capital requirement.
J&J secures FDA clearance for MONARCH QUEST 3 bronchoscopy system 2026-08-18
J&J secures FDA clearance for MONARCH QUEST 3 bronchoscopy system
Stocktwits 2026-08-18
Why Did ROKU, MRK, SCHW Stocks Jump To 52-Week Highs?
Yahoo Finance 2026-08-18
Elite Pharmaceuticals Inc (ELTP) (Q1 2027) Earnings Call Highlights: Steady Revenue and ...
Yahoo Finance 2026-08-19
Why Pfizer (PFE) Stock Is Trading Up Today — Shares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial results from peers Merck and Moderna for an mRNA cancer treatment lifted sentiment across the pharmaceutical sector.
Yahoo Finance 2026-08-19
Why this mRNA cancer vaccine is raising new treatment hope
Yahoo Finance 2026-08-19
Novavax (NVAX) Shares Skyrocket, What You Need To Know — Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 6.9% in the afternoon session after positive trial results from peers Moderna and Merck for their personalized cancer vaccine boosted sentiment across the vaccine sector.
Yahoo Finance 2026-08-19
BioNTech Stock Surges 22% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
The Motley Fool 2026-08-19
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data
Yahoo Finance 2026-08-19
Merck (MRK) Stock Trades Up, Here Is Why — Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 11.3% in the afternoon session after the company and its partner Moderna announced that their personalized mRNA cancer vaccine succeeded in a late-stage trial.
Yahoo Finance 2026-08-19
Update: Equities Snap 3-Day Losing Streak as Traders Parse July Fed Minutes
Yahoo Finance 2026-08-19
Stocks Hitch a Ride on the Bond Market's Rally — The Nasdaq Composite gained 0.2%.
Trefis 2026-08-19
Is AbbVie Stock About To Break Out Again?
Yahoo Finance 2026-08-19
Outpatient & Specialty Care Stocks Q2 Teardown: U.S. Physical Therapy (NYSE:USPH) Vs The Rest
Yahoo Finance 2026-08-19
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion? — Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
Yahoo Finance 2026-08-19
Merck Surges 7.5% After First Phase 3 mRNA Cancer-Vaccine Win
Yahoo Finance 2026-08-19
Moderna Shares Double After Cancer Vaccine Trial Delivers Major Win
Yahoo Finance 2026-08-19
Moderna, Merck Report Positive Phase 3 Trial Results of Melanoma Drug; Moderna Shares Jump Over 100%
Yahoo Finance 2026-08-19
Amgen Stock Surges 3.5% as Healthcare Hits Record High
Yahoo Finance 2026-08-19
Moderna Stock Surges on Stunning Cancer Update
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means 2026-08-19
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means — A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
Yahoo Finance 2026-08-19
OPK Raises $125 Million Against Royalties: What Investors Should Know — OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Yahoo Finance 2026-08-19
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
Yahoo Finance 2026-08-19
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going? — OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
Yahoo Finance 2026-08-19
Pfizer's Obesity Push: Can Berobenatide Take Market Share?
Yahoo Finance 2026-08-19
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
Yahoo Finance 2026-08-19
Moderna Skyrockets 90%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win
Yahoo Finance 2026-08-19
Moderna’s Cancer Breakthrough Just Sent the Stock Soaring 93%
Stocktwits 2026-08-19
MRNA Stock Heads For Its Best Ever Day After Melanoma Therapy Meets Primary Goal
Yahoo Finance 2026-08-19
Premarket movers: Moderna jumps after Phase 3 trial; Target slides
Yahoo Finance 2026-08-19
3 S&P 500 Stocks We Keep Off Our Radar
Yahoo Finance 2026-08-19
Moderna shares soar 60% on melanoma vaccine trial success
Yahoo Finance 2026-08-19
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wit
Yahoo Finance 2026-08-19
BioArctic and Mesenkia enter oncology research collaboration
24/7 Wall St. 2026-08-19
How Much Do You Need Invested at 55 to Bridge the Gap Until Social Security at 62?
Obesity investing’s way forward, mapped 2026-08-19
Obesity investing’s way forward, mapped
Yahoo Finance 2026-08-19
Stock market today: Dow, S&P 500, Nasdaq gain steam as bonds rally, Trump pauses tariffs on Canadian goods
Yahoo Finance 2026-08-19
What This Top Biotech Fund Is Buying Now — Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%
Yahoo Finance 2026-08-19
Cantargia Publishes Half-Year Report 2026
Yahoo Finance 2026-08-19
Johnson & Johnson’s Dividend Looks Well Positioned for the Long Term — In April 2026, the company raised its dividend by 3.1%, bringing the quarterly payment to $1.34, or $5.36 a year.
Yahoo Finance 2026-08-20
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery? — (NYSE:MRK) disclosed holding 1,214,126 shares of micro-cap AI immunology firm Evaxion A/S (NASDAQ:EVAX). Evaxion shares bumped up 2% to $3.17 in early trading on the news.
Yahoo Finance 2026-08-20
Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note — In the latest trading session, Johnson & Johnson (JNJ) closed at $267.37, marking a -2.21% move from the previous day.
Yahoo Finance 2026-08-20
NurExone Announces Closing of C$1,066,078 Private Placement — (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“Units”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “Offering”), subject to final acceptance of the TSX Venture Exchange
Yahoo Finance 2026-08-20
BioSyent Releases Financial Results for Q2 and H1 2026 — Key highlights include: (CAD)Q2 2026 % Changevs. Q2 2025 H1 2026 % Changevs. H1 2025 TTMJun 30, 2026 % Changevs.
Yahoo Finance 2026-08-20
Why Moderna (MRNA) Stock Is Trading Lower Today — Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.
Yahoo Finance 2026-08-20
Morgan Stanley Revamps Merck Stock Target After Cancer Breakthrough
Yahoo Finance 2026-08-20
Johnson & Johnson (JNJ) On Strong Results And 2026 Outlook Why Valuation Is Back In Focus — Johnson & Johnson (JNJ) is back in focus after its stock moved higher following a 6.6% rise in second quarter sales and an improved outlook for 2026. The recent second quarter update and regulatory news around Johnson & Johnson's MONARCH QUEST 3 system have come alongside strong momentum, with a 30 day share price return of 9.88% and an 81.38% total shareholder return over three years.
Yahoo Finance 2026-08-20
Merck Slips After 12.6% Cancer-Vaccine Surge
Yahoo Finance 2026-08-20
Moderna Is Up 350% Since Our Recommendation. Here’s What to Do Next.
Trefis 2026-08-20
Moderna's Melanoma Result Landed On A Market Positioned The Other Way
Yahoo Finance 2026-08-20
Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win — RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.
Stocktwits 2026-08-20
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight — BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.
TheStreet 2026-08-20
135-year-old healthcare giant surges on cancer vaccine breakthrough
Proactive Investors 2026-08-20
Moderna oncology platform draws Street value after melanoma trial win
24/7 Wall St. 2026-08-20
Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177%
Yahoo Finance 2026-08-20
Merck's Momentum Remains Strong But Valuation Limits Further Upside, RBC Says
24/7 Wall St. 2026-08-20
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Yahoo Finance 2026-08-20
1 S&P 500 Stock to Research Further and 2 That Underwhelm
Yahoo Finance 2026-08-20
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion — After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.
Yahoo Finance 2026-08-20
Innovative Eyewear, Inc. Announces Major New AI and News Features for Lucyd App
Yahoo Finance 2026-08-20
Moderna (MRNA) Is Up 173.9% After First Successful Phase 3 Individualized mRNA Cancer Therapy Trial - What's Changed
InvestorsHub 2026-08-20
Moderna shares slide as investors lock in gains after historic cancer vaccine rally
Stocktwits 2026-08-20
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
Yahoo Finance 2026-08-20
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough
Stocktwits 2026-08-20
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
Yahoo Finance 2026-08-20
Pfizer (PFE) Faces Fresh Legal Questions, Does It Look Fully Valued? — Pfizer's share price has responded to this mix of legal headlines, product updates and insider buying, with a 1-day share price return of 3.63%, a 30-day share price return of 14.10%, and a 1-year total shareholder return of 19.07%...
Stocktwits 2026-08-21
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation — The stock has gained over 20% in the past five days, marking its best week since early July.
Yahoo Finance 2026-08-21
Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats Up — Merck’s recent mRNA melanoma result has arrived alongside powerful price momentum, with a 30 day share price return of 18.0% and a year to date share price return of 40.0%.
Yahoo Finance 2026-08-21
Thank Moderna for the Healthcare Sector’s Standout Week — Moderna stock saw its best weekly performance ever, rising over 140%.
Yahoo Finance 2026-08-21
Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players
Trefis 2026-08-21
Lilly's Multiple Assumes Less Growth Than You Think
Yahoo Finance 2026-08-21
2 Reasons to Watch PFE and 1 to Stay Cautious — Pfizer has been treading water for the past six months, recording a small return of 2.6% while holding steady at $27.76. The stock also fell short of the S&P 500’s 12.7% gain during that period.
Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet. 2026-08-21
Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.
Trefis 2026-08-21
Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening
Trefis 2026-08-21
Most Of What Moves AbbVie Stock Has Nothing To Do With The Market
Yahoo Finance 2026-08-21
HALO Stock Rises 36% in a Month: Here's What You Should Know — Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
Yahoo Finance 2026-08-21
Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
Yahoo Finance 2026-08-21
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
Yahoo Finance 2026-08-21
Merck's Near-Term Catalysts Create Bull-Bear Debate, RBC Capital Markets Says
Yahoo Finance 2026-08-21
Form 8.3
Yahoo Finance 2026-08-21
Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
Yahoo Finance 2026-08-21
Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy. — The home to some large pharma companies and many smaller biotechs, have risen over 6% this week.
Yahoo Finance 2026-08-21
Christina Lake Cannabis Announces Non-Binding Letter of Intent
Yahoo Finance 2026-08-21
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care — Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens1This immunotherapy doublet regimen demonstrated durable disease control as early as second line, with more than 90% of patients who w…
Stocktwits 2026-08-21
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology — Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
24/7 Wall St. 2026-08-22
How a 53-Year-Old Can Turn $465,000 Into a Monthly Paycheck Machine by 63 — Starting yield and dividend growth pull $465,000 in two very different directions over a decade, and choosing the wrong one at 53 could cost you far more than the yield gap suggests.
The Motley Fool 2026-08-22
Prediction: This Is Where Pfizer Stock Will Be in 2030
Yahoo Finance 2026-08-23
Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff? — The pharmaceutical giant reported a 1% year-over-year operational increase in fiscal Q2 2026 revenue to $15.0 billion, while revenue excluding Comirnaty and Paxlovid grew 5% operationally.
Yahoo Finance 2026-08-23
Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over? — Johnson & Johnson (NYSE:JNJ) has proposed a whopping $5.5 billion settlement to resolve tens of thousands of lawsuits that allege its baby powder and ‌other talc products cause ovarian cancer.
Yahoo Finance 2026-08-23
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?
The Motley Fool 2026-08-23
Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?
24/7 Wall St. 2026-08-23
How to Build $6,600 a Month in Dividend Income From Three Income Buckets — Reaching $6,600 a month in dividend income sounds like a single-number problem, but the capital you actually need swings by more than a million dollars depending on which yield tier you choose and what you give up to get there.
24/7 Wall St. 2026-08-23
How to Build $11,800 a Month in Dividend Income Without Selling a Single Share — Collecting over $141,000 a year in dividends without selling a single share sounds like a fantasy until you realize the yield you chase determines whether your income grows, stagnates, or quietly cannibalizes itself.
Yahoo Finance 2026-08-23
Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma
24/7 Wall St. 2026-08-23
The Portfolio Blueprint for Building $19,000 a Month in Dividend Income — Generating $19,000 a month from dividends alone sounds like a single problem with one answer, but the yield you chase changes the required nest egg by millions and introduces a completely different set of risks, tax consequences, and long-term tradeoffs.
24/7 Wall St. 2026-08-24
How to Build $7,800 a Month in Dividend Income Without Owning a Single Yield Trap
Yahoo Finance 2026-08-24
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
The Motley Fool 2026-08-24
D-Wave Quantum vs. Rigetti Computing: Which Quantum Computing Stock Is a Better Investment in 2026?
24/7 Wall St. 2026-08-24
How to Build $3,100 a Month in Dividend Income Starting From Zero — Building $37,200 a year in dividend income is a math problem first, and the yield tier you choose changes the capital required by hundreds of thousands of dollars in ways most investors never calculate before picking their first stock.
Yahoo Finance 2026-08-24
Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
Stocktwits 2026-08-24
GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict
Yahoo Finance 2026-08-24
Johnson & Johnson Rises 1.3% as Investors Seek Stability
Trefis 2026-08-24
Moderna Stock Had A Readout Waiting In Plain Sight
Yahoo Finance 2026-08-24
Analysts See Drastic Change For This Particular Part Of Healthcare — While Moderna shares have remained volatile since then — down 23.5% Thursday after rising 177% Wednesday — the biotech ETF is doing its job as a diversified fund, keeping its one-day price moves to within 6%.
Yahoo Finance 2026-08-24
Will LQDA's Differentiated PAH Approach Drive Growth?
Trefis 2026-08-24
Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition
Yahoo Finance 2026-08-24
Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson — DALLAS, August 24, 2026--Texas trial law firm Dean Omar Branham Shirley, LLP (DOBS) has secured a $10 million jury verdict in a mesothelioma case brought on behalf of the family of Lynne Roy, a Louisiana woman who died in 2020 after developing the deadly lung disease mesothelioma following decades of exposure to talc products.
24/7 Wall St. 2026-08-24
Eli Lilly Has a $100 Billion Revenue Story in the Making, 18% Upside Ahead — Eli Lilly just crossed a $1 trillion market cap for the first time, and management is already pointing toward a milestone that would rewrite the drugmaker's history.
24/7 Wall St. 2026-08-24
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips — Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful unwind for latecomers.
Yahoo Finance 2026-08-24
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
24/7 Wall St. 2026-08-24
Pfizer Stock: Wall Street Sees a Rebound, Here’s Our Price Target
Yahoo Finance 2026-08-24
Moderna Is Betting Big on Its Cancer Vaccine. This Is What Wall Street Wants to See.
Yahoo Finance 2026-08-24
J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead
Yahoo Finance 2026-08-24
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
TheStreet 2026-08-24
A cancer vaccine years in the making just proved itself
Yahoo Finance 2026-08-24
1 Stock Under $50 to Research Further and 2 Facing Headwinds — Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
24/7 Wall St. 2026-08-24
Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze
Yahoo Finance 2026-08-24
GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies
Analysts praise intismeran’s landmark Phase III win, look to further data 2026-08-24
Analysts praise intismeran’s landmark Phase III win, look to further data
Trefis 2026-08-24
What Is Really Moving Tempus AI Stock Right Now?
Related: Pfizer and large-cap pharma value recovery 2026-08-25
Spillover from a related thesis (semantic)
Related: Healthcare rotation as AI selloff hedge 2026-08-25
Spillover from a related thesis (semantic)
Related: mRNA platform expansion beyond vaccines 2026-08-25
Spillover from a related thesis (semantic)
Related: Healthcare managed care and aging demographics 2026-08-25
Spillover from a related thesis (shares holding)
Related: Healthcare rotation as AI selloff hedge 2026-08-25
Spillover from a related thesis (shares holding)
Related: Pfizer and large-cap pharma value recovery 2026-08-25
Spillover from a related thesis (shares holding)
Related: Johnson & Johnson healthcare earnings quality 2026-08-25
Spillover from a related thesis (shares holding)
Yahoo Finance 2026-08-25
Does Louisiana’s US$10 Million Talc Verdict Shift the Legal Risk Bull Case For Johnson & Johnson (JNJ)? — In August 2026, a Louisiana jury awarded US$10.00 million in a mesothelioma case linked to decades of talc exposure, assigning Johnson & Johnson over US$1.20 million of the liability while finding its talc products unreasonably dangerous and inadequately labeled regarding asbestos risks.
Yahoo Finance 2026-08-25
LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
Trefis 2026-08-25
The Hospital Bet That Reframes The Intuitive Surgical Stock Story
Yahoo Finance 2026-08-25
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
24/7 Wall St. 2026-08-25
Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name? — Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector.
Yahoo Finance 2026-08-25
Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway? — (NYSE:MRK) jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna.
24/7 Wall St. 2026-08-25
How Much Do You Really Need Invested to Replace a $120,000 Salary With Dividends? — The yield you chase determines whether you need $1 million or $3.4 million, and the one that feels safest might quietly betray you a decade from now.
24/7 Wall St. 2026-08-25
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
Trefis 2026-08-25
Dell Stock's Massive Guidance Raise Has A Catch
Yahoo Finance 2026-08-25
Acquisition of Own Shares — Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 17, 2026 and August 21, 2026, it has repurchased 117,471 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchaseMarket/MTFNumber of sharesAverage pric…
24/7 Wall St. 2026-08-25
Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200? — Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire post-KEYTRUDA story.
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? 2026-08-25
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?
Stocktwits 2026-08-25
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
The Motley Fool 2026-08-25
3 Dividend Stocks to Hold for the Next 10 Years
Yahoo Finance 2026-08-25
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
Trefis 2026-08-25
Eli Lilly Found a New Gear. You Paid For It.
Wolfe Research Just Upgraded Moderna Stock. Here's Why. 2026-08-25
Wolfe Research Just Upgraded Moderna Stock. Here's Why.
Yahoo Finance 2026-08-25
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Yahoo Finance 2026-08-25
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum — BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
Yahoo Finance 2026-08-25
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
24/7 Wall St. 2026-08-25
How Large Does Your Portfolio Need to Be to Generate $16,500 a Month?
Yahoo Finance 2026-08-25
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue — BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.
Yahoo Finance 2026-08-25
J&J's First-In-Disease Approval Barely Moves a $666 Billion Stock
Yahoo Finance 2026-08-25
Moderna Stock Soars on Cancer Vaccine Breakthrough
Yahoo Finance 2026-08-25
How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds? — AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.
J&J’s Imaavy secures expanded US approval in rare blood disorder 2026-08-25
J&J’s Imaavy secures expanded US approval in rare blood disorder — The FDA approval marks another successful step in J&J’s aim of achieving $5bn in peak sales for the drug.
Stocktwits 2026-08-26
Why Did RUM, MRK, NEM Stocks Jump To 52-Week Highs Today?
Yahoo Finance 2026-08-26
Pfizer (PFE) Starts EMA Review For Its Lyme Disease Vaccine
24/7 Wall St. 2026-08-26
Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips — Moderna stock shed 7% on Wednesday with no company news to blame, reopening a brutal question that its 439% year-to-date rally had been drowning out: what exactly does a $59 billion valuation buy on a revenue base this thin?
Trefis 2026-08-26
Moderna Stock Carries A Market Value Its Revenue Does Not Support
24/7 Wall St. 2026-08-26
Dividends vs. an Annuity: Which Turns $840,000 Into More Monthly Income for Life? — A nest egg of $840,000 sits right at the crossroads where dividends and annuities each look surprisingly compelling, and where the wrong choice quietly costs you tens of thousands of dollars over a 20-year retirement.
Yahoo Finance 2026-08-26
SimuTech Group Engineers Co-Author Chapter in Open-Access Medical Device VVUQ Handbook
Yahoo Finance 2026-08-26
Merck Stock Hits New 52-Week High: What's Driving the Rally?
Yahoo Finance 2026-08-26
Atrial Fibrillation Market Trends and Forecast 2026-2035 Featuring Profiles of Abbott, Boston Scientific, Medtronic, Johnson & Johnson, Novartis, and Sanofi — Antiarrhythmic agents account for around 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach Atrial Fibrillation Market Atrial Fibrillation Market Dublin, Aug.
24/7 Wall St. 2026-08-26
How Much Do You Need Invested by 55 to Retire on Dividends at 65?
Yahoo Finance 2026-08-26
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know — In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $270.27, denoting a -1.05% move from the preceding trading day.
Yahoo Finance 2026-08-26
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Trefis 2026-08-26
Time To Squeeze 14% Yield Out Of Battered BSX Stock?
The Motley Fool 2026-08-26
I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now
Yahoo Finance 2026-08-26
J&J's First Anemia Approval Meets a $652 Billion Reality
The Motley Fool 2026-08-26
My 2 Favorite Dividend Stocks to Buy in August
Yahoo Finance 2026-08-26
Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? — Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion.
Yahoo Finance 2026-08-26
Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
Yahoo Finance 2026-08-26
InnovAge Announces Conference Call to Discuss Fourth Quarter and Fiscal 2026 Financial Results and Participation in Upcoming Wells Fargo Healthcare Conference
Yahoo Finance 2026-08-26
Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
Metsera backers establish new biotech armed with China-licensed immunology asset 2026-08-26
Metsera backers establish new biotech armed with China-licensed immunology asset
24/7 Wall St. 2026-08-26
5 Blue-Chip Dividend Stocks to Buy Before August Ends
Yahoo Finance 2026-08-27
Market Chatter: Novo Nordisk Reports China Regulators Accept Weight-Loss Drug Application
Stocktwits 2026-08-27
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future — ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
The Motley Fool 2026-08-27
Johnson & Johnson Just Got a Big FDA Win
Yahoo Finance 2026-08-27
How Investors May Respond To Natera (NTRA) New MRD Trial Deal And Duquesne Stake Expansion
Yahoo Finance 2026-08-27
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Trefis 2026-08-27
Can Cost Cuts And 2030 Targets Really Save Pfizer Stock?
Yahoo Finance 2026-08-27
What Is Johnson & Johnson (JNJ) Telling Investors With Its First WAIHA Approval?
Yahoo Finance 2026-08-27
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
Yahoo Finance 2026-08-27
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs? — LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.
Stocktwits 2026-08-27
Moderna’s $2B Convertible-Note Deal To Focus On Oncology Growth, Debt Repayment – But Retail Calls It A ‘Bull Trap’ — The biotech firm announced plans to raise $2 billion through convertible notes, which could be increased to $2.3 billion.
Yahoo Finance 2026-08-27
BioNTech (BNTX) Rallied on Moderna’s Win. Does a Competitor’s Success Validate its Oncology Pipeline?
Yahoo Finance 2026-08-27
Slate Medicines Starts Migraine Treatment Study
Yahoo Finance 2026-08-27
HealthEquity Inc (HQY) (Q2 2027) Earnings Call Highlights: Record Revenue and Margin Expansion ... — HealthEquity Inc (HQY) delivers record Q2 results with 8% revenue growth and a 48% adjusted EBITDA margin, fueled by AI-driven efficiencies and strong HSA member engagement.
Yahoo Finance 2026-08-27
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
The Motley Fool 2026-08-27
I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now
24/7 Wall St. 2026-08-27
This $1.75 Million Portfolio Pays $10,200 a Month From Three Income Buckets — Chasing a 7% blended yield across a $1.75 million portfolio sounds straightforward until you realize that loading up on the highest payers quietly destroys the very income stream you built.
Yahoo Finance 2026-08-27
Artivion (AORT) Stock Looks Cheap On Cash Flow But Pricey On Sales — Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount. Artivion is up 57.6% over three years.
Yahoo Finance 2026-08-27
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
24/7 Wall St. 2026-08-27
Wall Street Is Sleeping on These 3 Ultra-High-Yield Dividend Stocks
Trefis 2026-08-27
Has BSX Stock Fallen Far Enough To Buy?
Trefis 2026-08-28
Amgen Stock Signals Its Confidence. The Market Agrees.
Yahoo Finance 2026-08-28
Merck (MRK) Stock Looks Fully Priced After A 127% Run — Over 5 years, Merck has returned 126.6%, which sets expectations high for what investors are willing to pay for the next leg of the...
Trefis 2026-08-28
Can ISRG Stock Defend Its $131B Valuation?
Yahoo Finance 2026-08-28
New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst
Yahoo Finance 2026-08-28
Alligator Bioscience AB (STU:7AL0) (Q2 2026) Earnings Call Highlights: Strategic Pivot to HLX22 ...
Yahoo Finance 2026-08-28
Cytotoxic Drugs Market Report Now Available — Forecasts Market Growth from $16.21B (2026) to $21.06B by 2031, Profiling Pfizer, Roche, Novartis, AstraZeneca, Sanofi, and 15 Other Key Players — Cytotoxic Drugs Market to Reach USD 21.06 Billion by 2031 as Cancer Treatment Demand Expands The global cytotoxic
Yahoo Finance 2026-08-28
The Bull Case For Pfizer (PFE) Could Change Following New COVID And Lyme Vaccine Milestones - Learn Why
Yahoo Finance 2026-08-28
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
24/7 Wall St. 2026-08-28
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
Yahoo Finance 2026-08-28
AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
Yahoo Finance 2026-08-28
BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win
Yahoo Finance 2026-08-28
Form 8.3
Yahoo Finance 2026-08-28
BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast — Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior.
Yahoo Finance 2026-08-28
Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial — On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do.
Trefis 2026-08-28
Did A Product Swap Fuel JNJ Stock’s 54% Surge?
Yahoo Finance 2026-08-28
Pfizer's Updated COVID Shot Ships Into a Smaller Market
Yahoo Finance 2026-08-28
BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall
Yahoo Finance 2026-08-28
Johnson & Johnson (NYSE:JNJ) Has A Better Balance Sheet Than The Government, Said Jim Cramer
Stocktwits 2026-08-28
BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’
Trefis 2026-08-28
Can Merck Stock Outrun Its Pipeline?
Yahoo Finance 2026-08-28
Moderna (MRNA) & Merck (MRK): What’s Happening With These Two Stocks? — The news sent Moderna shares up as much as 177%, adding $44 billion to its market value, while Merck […]
Yahoo Finance 2026-08-28
Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial — (NYSE:MRK) said their personalized melanoma vaccine, intismeran, combined with Merck’s Keytruda, met its goals in a Phase 3 trial of 1,137 patients.
The Motley Fool 2026-08-28
Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.
Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points. 2026-08-28
Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.
24/7 Wall St. 2026-08-28
Cashing Out a Pension or Taking the Monthly Check? The Dividend Answer for a $610,000 Lump Sum — A $610,000 pension lump sum sounds like freedom, but the monthly check comes with a guarantee that a dividend portfolio simply cannot replicate.
24/7 Wall St. 2026-08-28
What a $1.55 Million Portfolio Actually Pays After Taxes, Medicare Premiums, and Reality — What actually clears into your checking account from $1.55 million depends on decisions most retirees never see coming.
Yahoo Finance 2026-08-28
Lobe Sciences Expands Leadership Team with New CFO Appointment
Yahoo Finance 2026-08-28
J&J's China Pill Win Challenges Its Own Injection Franchise
Yahoo Finance 2026-08-29
Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb — The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]
Yahoo Finance 2026-08-29
INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces — SZ), a leading global manufacturer of disposable gloves, reported revenue of RMB 6.91 billion (approx. US$1.03 billion) for the six months ended June 30, 2026, up 40.61% from a year earlier. Net profit attributable to shareholders rose 17.86% to RMB 837.3 million (approx.
Yahoo Finance 2026-08-29
Hims & Hers Health (HIMS) Is Down 14.6% After Raising Guidance Amid Privacy Scrutiny - What's Changed — Earlier this week, Hims & Hers Health reported quarterly revenue of US$753.2 million, up 38.2% year on year, added 307,000 customers to reach 2.89 million, and raised both next-quarter revenue guidance and full-year EBITDA guidance above analyst expectations.
Yahoo Finance 2026-08-29
Teleflex (TFX) Stock Trades At A Discount On Cash Flow But A Premium On Sales — Teleflex has fallen about 63.6% over five years, which means recent gains still sit against a deep...
The Motley Fool 2026-08-29
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector? 2026-08-29
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?
Yahoo Finance 2026-08-30
Healthcare’s Best Week Since June Traces Back to a Single Moderna and Merck Cancer Trial — The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June.
24/7 Wall St. 2026-08-30
How a 79-Year-Old Widow Built a $6,100 Monthly Paycheck Around O, JNJ, and PFF
Yahoo Finance 2026-08-30
Merck (MRK) Posts First Positive Phase 3 Result For Personalized mRNA Melanoma Therapy
Yahoo Finance 2026-08-31
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
Yahoo Finance 2026-08-31
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
24/7 Wall St. 2026-08-31
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t
Yahoo Finance 2026-08-31
Oligomerix Appoints Biopharmaceutical Industry Veteran Cara Cassino, M.D. as Interim President and Chief Executive Officer
Yahoo Finance 2026-08-31
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
Yahoo Finance 2026-08-31
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
Yahoo Finance 2026-08-31
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Yahoo Finance 2026-08-31
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Yahoo Finance 2026-08-31
Pfizer (PFE) Reaches Confidential Settlement In Depo Provera Litigation — The agreement reportedly addresses more than 6,000 cases, with financial terms not disclosed and no admission of liability by Pfizer.
24/7 Wall St. 2026-08-31
JEPI’s Monthly Payouts Shrunk as the Bull Market Raged. Here’s When That Changes
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment 2026-08-31
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
24/7 Wall St. 2026-08-31
This Popular Healthcare ETF Is Diluting Your Dividend Income
Yahoo Finance 2026-08-31
There Was No Beating Moderna in August. These Are the Best and Worst S&P 500 Stocks for the Month. — Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.
Yahoo Finance 2026-08-31
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
Yahoo Finance 2026-08-31
Chris Benecchi Named Inventiva’s New Chief Operating Officer
Trefis 2026-09-01
The Peer-Group Mispricing Sitting On BSX Stock
Yahoo Finance 2026-09-01
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges
The Motley Fool 2026-09-01
Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
Yahoo Finance 2026-09-01
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Yahoo Finance 2026-09-01
Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023.
24/7 Wall St. 2026-09-01
Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story
Yahoo Finance 2026-09-01
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging
Yahoo Finance 2026-09-01
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance 2026-09-01
Harrow to Participate in Three Investor Conferences in September
Yahoo Finance 2026-09-01
Pennant Group to Participate in the 2026 Jefferies Healthcare Services Conference
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment 2026-09-01
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
Yahoo Finance 2026-09-01
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors — (TLRY) concluded the recent trading session at $4.5, signifying a -1.53% move from its prior day's close.
Yahoo Finance 2026-09-01
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
Yahoo Finance 2026-09-01
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts — Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.
24/7 Wall St. 2026-09-01
Three Dividend Kings That Pay a 75-Year-Old $3,900 a Month: KO, JNJ, and PEP — Replacing nearly $47,000 a year in retirement income without touching principal sounds like a math problem, but the real trap is choosing the wrong yield tier and watching either your paycheck or your nest egg quietly shrink.
Yahoo Finance 2026-09-01
Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding
Yahoo Finance 2026-09-01
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance 2026-09-02
Yahoo Finance 2026-09-02
GSK (LSE:GSK) Wins First Global Approval For Chronic Hepatitis B Functional Cure
Yahoo Finance 2026-09-02
Simply Solventless Files Q2 2026 Financials and Provides Updates on Management Cease Trade Order, Private Placement and Debt Settlement
Stocktwits 2026-09-02
Why Did PFE, MMED, DE Stocks Surge To 52-Week Highs Today?
Yahoo Finance 2026-09-02
GSK (LSE:GSK), What Is Behind The Latest Attention? — Against this backdrop of pipeline news, GSK’s share price has shown mixed short term momentum, with a 1-day share price return of 0.97% but a 30-day share price return that is down 3.11%, while the 1-year total shareholder return of 34.36% points to much stronger longer term...
Yahoo Finance 2026-09-02
Does Johnson & Johnson (JNJ) Talc Verdict Add To Its Legal Risk?
Yahoo Finance 2026-09-02
How Investors Are Reacting To Merit Medical Systems (MMSI) New Global Operations Leadership Transition
Yahoo Finance 2026-09-02
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks — Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money.
Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology 2026-09-02
Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology
Yahoo Finance 2026-09-02
1 Value Stock with Impressive Fundamentals and 2 Facing Headwinds
Yahoo Finance 2026-09-02
Organigram Global to Host 2026 OG Investor Session
Takeda and Weave Bio collaborate on AI-driven automation in drug development 2026-09-02
Takeda and Weave Bio collaborate on AI-driven automation in drug development
The Motley Fool 2026-09-02
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
Yahoo Finance 2026-09-02
ImExHS Ltd (ASX:IME) (H1 2026) Earnings Call Highlights: EBITDA Quadruples to $1. ... — ImExHS Ltd (ASX:IME) reports a 17% revenue increase to $16 million, with contracted ARR more than doubling to $4.4 million, setting the stage for FY26 guidance of up to $33.7 million in revenue.
Yahoo Finance 2026-09-02
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies — (Nasdaq: CDT) (“CDT” or the “Company”) today announced that, following the recent issuance of shares and the exercise of pre-funded warrants, the Company had 13,693,866 shares of Common Stock issued and outstanding as of August 31, 2026. Based on the closing price of CDT’s Common Stock on August 31, 2026, the Company had a market capitalisation of approximately $23.0 million.
Yahoo Finance 2026-09-02
Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical Officer
Yahoo Finance 2026-09-02
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Yahoo Finance 2026-09-02
UniQure's Embattled Huntington's Gene Therapy Clears A Key Hurdle
Yahoo Finance 2026-09-02
Johnson & Johnson's Drug Pipeline Supports Growth Outlook, UBS Securities Says
Yahoo Finance 2026-09-02
Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy
Yahoo Finance 2026-09-02
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says
Yahoo Finance 2026-09-02
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Yahoo Finance 2026-09-02
MKSI or HOCPY: Which Is the Better Value Stock Right Now?
Yahoo Finance 2026-09-02
Silchester International Investors - Press Release and EGM Demand Letter - Medipal Holdings Corporation (7459:JT)
Yahoo Finance 2026-09-02
Sector Update: Healthcare Stocks Advance Late Afternoon
Trefis 2026-09-02
ISRG Stock: The Best House On The Block Costs The Most
The Motley Fool 2026-09-02
Is BioNTech Stock a No-Brainer Buy on the Dip?
Trefis 2026-09-02
Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
Yahoo Finance 2026-09-02
3 AI Stocks To Watch With Up To 45% Earnings Growth
Trefis 2026-09-02
The Wide Divide Priced Into Boston Scientific Stock
Yahoo Finance 2026-09-02
Sector Update: Healthcare Stocks Advance Wednesday Afternoon — Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th
Trefis 2026-09-02
Amgen Stock Signals Its Confidence. The Market Agrees.
The Motley Fool 2026-09-02
Should You Buy Pfizer Stock Below $30?
Trefis 2026-09-02
How Did Merck Stock Beat The Market With Slowing Sales?
Yahoo Finance 2026-09-02
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Yahoo Finance 2026-09-02
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Yahoo Finance 2026-09-02
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
Yahoo Finance 2026-09-02
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Yahoo Finance 2026-09-02
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Yahoo Finance 2026-09-02
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
Yahoo Finance 2026-09-02
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Yahoo Finance 2026-09-02
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
Yahoo Finance 2026-09-02
J&J Jumps as UBS Lifts Its Target to $320 — The new objective implies roughly 16% upside and reflects stronger expectations for J&J's pharmaceutical pipeline.
Stocktwits 2026-09-03
Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today?
AbbVie could take BiTE of Tecvayli market share on Phase III MM win 2026-09-03
AbbVie could take BiTE of Tecvayli market share on Phase III MM win
Trefis 2026-09-03
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
Yahoo Finance 2026-09-03
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Yahoo Finance 2026-09-03
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
Trefis 2026-09-03
Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided? — The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high.
Yahoo Finance 2026-09-03
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop
Yahoo Finance 2026-09-03
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
Yahoo Finance 2026-09-03
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
Yahoo Finance 2026-09-03
Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning
Yahoo Finance 2026-09-03
Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.
Yahoo Finance 2026-09-03
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Yahoo Finance 2026-09-03
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
The Motley Fool 2026-09-03
3 Things You Need to Know If You Buy Pfizer Stock Today
Yahoo Finance 2026-09-03
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Trefis 2026-09-03
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Yahoo Finance 2026-09-03
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Yahoo Finance 2026-09-04
Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check — Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...
Yahoo Finance 2026-09-04
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China — Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
24/7 Wall St. 2026-09-04
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying? — Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
Yahoo Finance 2026-09-04
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
24/7 Wall St. 2026-09-04
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug 2026-09-04
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal 2026-09-04
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Yahoo Finance 2026-09-04
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know — Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.
The Motley Fool 2026-09-04
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Trefis 2026-09-04
How Much Upside Can BSX Stock's Growth Deliver? — Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Yahoo Finance 2026-09-04
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
Trefis 2026-09-04
Was JNJ Stock Rally Actually Its Own? — Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500.
24/7 Wall St. 2026-09-05
3 Dividend Kings Built to Keep Raising Your Income When Rates Rise
Yahoo Finance 2026-09-07
Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pip — One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 481 Targets, 350 Deals, and 1,100+ Funding Rounds as Amgen, Roche, and J&J Lead a Field That Saw 278 New Drugs in 2024/25 AloneDublin, Sept.
Yahoo Finance 2026-09-07
Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery
Yahoo Finance 2026-09-07
Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
24/7 Wall St. 2026-09-07
Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?
Yahoo Finance 2026-09-07
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah — AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.
Yahoo Finance 2026-09-07
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva — The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period.
24/7 Wall St. 2026-09-07
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now — Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.
Yahoo Finance 2026-09-07
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI 2026-09-08
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
Novartis India acquires Pfizer brands for $132m 2026-09-08
Novartis India acquires Pfizer brands for $132m
Yahoo Finance 2026-09-08
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio — The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by ri
Yahoo Finance 2026-09-08
The Hashgraph Group and Merck with support from PwC Germany develop solution for cocoa traceability and digital product passports
Yahoo Finance 2026-09-08
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell? — Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
Yahoo Finance 2026-09-08
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
InvestorsHub 2026-09-08
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy
24/7 Wall St. 2026-09-08
Want Dividends to Pay Your Medicare Premiums? Here’s How Much You Need
Yahoo Finance 2026-09-08
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
Yahoo Finance 2026-09-08
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Yahoo Finance 2026-09-08
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
The Motley Fool 2026-09-08
Why Pfizer Stock Was so Healthy in August
Yahoo Finance 2026-09-08
Protagonist Therapeutics Announces $300 Million Share Repurchase Program — (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock.
Yahoo Finance 2026-09-08
Exclusive: J&J Snack Foods CEO sees a leaner business set up to return to growth
Trefis 2026-09-08
Is AbbVie Stock Too Reliant On Skyrizi? — AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500.
The Motley Fool 2026-09-08
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now — Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.
Yahoo Finance 2026-09-08
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
24/7 Wall St. 2026-09-08
JEPI Is an Income Machine—But These 3 Dividend Stocks Don’t Cap Your Upside
Yahoo Finance 2026-09-08
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Yahoo Finance 2026-09-09
Influenza A Market Insight, Epidemiology, and Market Forecast - 2036 Now Available — See Why a 70% Vaccine Failure Rate Is Fueling the Race for Next-Gen Flu Therapies
Yahoo Finance 2026-09-09
VERAXA Biotech Designates Raju Willener as CFO
Yahoo Finance 2026-09-09
Wellcome Leap Appoints John Young and Thomas Glanzmann to Board of Directors
Yahoo Finance 2026-09-09
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
24/7 Wall St. 2026-09-09
How Large Does Your Portfolio Need to Be to Generate $12,500 a Month? — A seven-holding portfolio promising $12,500 a month sounds straightforward until you examine whose money is actually funding some of those distributions, and why the highest-yielding positions have the weakest claim to keeping their promises.
24/7 Wall St. 2026-09-09
How a 74-Year-Old Collects $8,900 a Month Without Selling a Single Share — Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.
Yahoo Finance 2026-09-09
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
24/7 Wall St. 2026-09-09
Paying Off the House With Your 401(k) Feels Smart but Can Cost Six Figures. These 3 ETFs Are Why You Keep the Money Invested
Trefis 2026-09-09
What Eli Lilly Was Telling You While It Rationed Its Own Launches — Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91.
Trefis 2026-09-09
How Much Can ISRG Stock Still Move Against You? — The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high.
Yahoo Finance 2026-09-09
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
Trefis 2026-09-09
BSX Stock: Is It Time To Buy Or Sell Puts? — Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.
Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage 2026-09-09
Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage — Johnson & Johnson (NYSE:JNJ) MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-m
Tyra disappoints investors with bladder cancer data 2026-09-09
Tyra disappoints investors with bladder cancer data
Yahoo Finance 2026-09-09
Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China? — The decision gives the company another route into a market where more than 8.4 million people are affected by psoriasis, according to J&J.
A new immuno-oncology play raises $225M for a next-generation drug 2026-09-09
A new immuno-oncology play raises $225M for a next-generation drug
Trefis 2026-09-10
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes — Amgen (AMGN) trades at about $393 a share.
Yahoo Finance 2026-09-10
China services trade fair showcases innovation, promotes openness
Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss 2026-09-10
Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss
Yahoo Finance 2026-09-10
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
Yahoo Finance 2026-09-10
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
Trefis 2026-09-10
Why Has AbbVie Gone Quiet About Humira? — AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape.
Yahoo Finance 2026-09-10
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Yahoo Finance 2026-09-10
Medicare’s $2,000 Drug Cap Is Getting Expensive — More Than 1 in 5 Seniors Hit It as Drug Spending Heads Toward $346 Billion — Health policy analysts are raising concerns about the rising cost of Medicare’s prescription drug program after more than 1 in 5 Medicare Part D enrollees hit the program’s $2,000 out-of-pocket drug cap in 2025.
Yahoo Finance 2026-09-10
2 Reasons Cooper Companies Stock Is By Far the Worst in the S&P 500 Today
Yahoo Finance 2026-09-10
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
Trefis 2026-09-10
Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?
Yahoo Finance 2026-09-10
Barron’s Got Cooper Wrong but the Contact-Lens Stock Now Looks Cheap — Cooper Cos. stock has fallen about 25% since Barron’s recommended it, but a low valuation, aggressive share buybacks, and takeover potential bolster the bull case.
Yahoo Finance 2026-09-10
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot 2026-09-10
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Trefis 2026-09-10
JNJ Stock: Is the Rally Running Out of Steam?
Trefis 2026-09-10
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
24/7 Wall St. 2026-09-10
Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy? — Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.
Yahoo Finance 2026-09-10
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy — Under the development and licensing agreement, Medicus has secured rights to a CD228-targeted antibody-drug conjugate (ADC) program, while Pfizer is contributing approximately $2 million in development funding, along with inventory and infr
Yahoo Finance 2026-09-10
Ritedose Appoints Carolyn Berg as New Vice President of Strategic Growth
mRNA cancer vaccines’ biggest barriers to market 2026-09-10
mRNA cancer vaccines’ biggest barriers to market
Yahoo Finance 2026-09-11
Advanced Bioreactor Systems Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036) — The global Advanced Bioreactor Systems Market is projected to grow from USD 4.2 billion in 2026 to USD 11.8 billion by 2036, at a CAGR of 10.9%.
24/7 Wall St. 2026-09-11
The Dividend Stocks That Generate $6,400 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)
24/7 Wall St. 2026-09-11
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat — Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.
Yahoo Finance 2026-09-11
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
Yahoo Finance 2026-09-11
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Yahoo Finance 2026-09-11
3 Top Dividend Aristocrats To Own Near All-Time Highs
24/7 Wall St. 2026-09-11
These 5 Dividend Stocks Survived 2008, COVID and Every Recession Before Them
24/7 Wall St. 2026-09-11
The 10-Year Treasury Pays Nearly 5% These 6 Dividend Stocks Still Pay More
Yahoo Finance 2026-09-11
U.S. Stock Funds Rebound In August And Snub Bond Market Warning
Yahoo Finance 2026-09-11
Jaguar LAA, Inc. Announces Acquisition of Assets Related to the Laminar Program
Trefis 2026-09-11
Is AbbVie Stock Actually Overpriced? — AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six.
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months 2026-09-11
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
Merck builds around Keytruda; prediction markets raise new risks 2026-09-11
Merck builds around Keytruda; prediction markets raise new risks
Stocktwits 2026-09-11
JNJ Stock Edges Up After-Hours On Apollo’s $20B Orthopedics Talks — People familiar with the discussions told Bloomberg that Apollo is working toward a valuation of close to $20 billion for the unit, known as DePuy Synthes.
Yahoo Finance 2026-09-11
Apollo Global Is Said in Talks to Acquire J&J’s Orthopedics Unit
The Motley Fool 2026-09-12
2 Outstanding Dividend Stocks to Buy and Hold for 10 Years
24/7 Wall St. 2026-09-12
The Closest Thing to Set-It-and-Forget-It Income: 5 Dividend Kings for Retirees Who Want Peace of Mind
The Motley Fool 2026-09-12
How Concerned Should Income Investors Be About Pfizer's Dividend? — Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.
Yahoo Finance 2026-09-12
Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock
Yahoo Finance 2026-09-13
C3.ai (AI) Just Posted Its Most Promising Quarter In Years — Total revenue reached $52.4 million, subscription revenue made up 94% of that at $49.2 million, and total bookings jumped 73% quarter over quarter.
Yahoo Finance 2026-09-14
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Yahoo Finance 2026-09-14
Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
Yahoo Finance 2026-09-14
Zacks Investment Ideas feature highlights: Johnson & Johnson, Coca-Cola and Exxon Mobil
Yahoo Finance 2026-09-14
Big Pharma Is Pouring Billions Into China’s Biotechs
Yahoo Finance 2026-09-14
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage 2026-09-14
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage
Yahoo Finance 2026-09-14
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types 2026-09-14
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
Trefis 2026-09-14
Get Paid To Wait For ISRG Stock To Go On Sale — Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed.
24/7 Wall St. 2026-09-14
4 High-Yield Dividend Stocks Worth Having in Your Roth IRA
Yahoo Finance 2026-09-14
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
24/7 Wall St. 2026-09-14
Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA
Stocktwits 2026-09-14
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation 2026-09-14
Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation
Trefis 2026-09-14
Is This LLY Stock Dip Big Enough To Be Worth Buying? — Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in.
Trefis 2026-09-14
Why Is Pfizer Stock Paying You So Much To Wait? — Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. A 6.2% dividend yield over the past twelve months is what that wait pays.
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition 2026-09-14
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business 2026-09-14
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results 2026-09-14
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
Quartz 2026-09-14
J&J in talks to sell DePuy Synthes to Apollo for $20 billion — Apollo is in discussions to acquire DePuy Synthes, which generated $9.3 billion in sales last year and could also be spun off as a public company
Yahoo Finance 2026-09-14
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
InvestorsHub 2026-09-14
Johnson & Johnson Shares Rise on Reported Apollo Talks for Orthopedics Unit — Johnson & Johnson (NYSE:JNJ) shares rose 1. 3% to $268.
24/7 Wall St. 2026-09-14
Pfizer’s 6% Yield Masks a Fragile Dividend Story
Yahoo Finance 2026-09-14
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
Yahoo Finance 2026-09-14
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Yahoo Finance 2026-09-14
IP Group eyes further value growth as cash realisations top £85m — IP Group PLC (LSE:IPO) CEO Greg Smith spoke with Proactive's Stephen Gunnion about a strong start to 2026, with NAV per share reaching around 117p and cash proceeds topping £85 million year to date. He also highlighted the wider portfolio, with companies raising more than £540 million of third-party
Stocktwits 2026-09-15
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals — J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
Yahoo Finance 2026-09-15
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
24/7 Wall St. 2026-09-15
3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
Yahoo Finance 2026-09-15
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Yahoo Finance 2026-09-15
Slate Medicines Names Kenneth Koblan as Chief Scientific Officer
Yahoo Finance 2026-09-15
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Yahoo Finance 2026-09-15
Apollo and J&J Face a High-Stakes Orthopedics Deal — (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction […]
Yahoo Finance 2026-09-15
AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss
Yahoo Finance 2026-09-15
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Yahoo Finance 2026-09-15
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Yahoo Finance 2026-09-15
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Trefis 2026-09-15
Has BSX Stock Finally Hit Bottom? — Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45.
Yahoo Finance 2026-09-15
Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat
Yahoo Finance 2026-09-15
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
24/7 Wall St. 2026-09-15
Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030
Yahoo Finance 2026-09-15
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
IP Group H1 Earnings Call Highlights 2026-09-15
IP Group H1 Earnings Call Highlights — Net asset value per share increased 3.2% during the half year to 114p
Yahoo Finance 2026-09-15
Merck & Co Inc's Dividend Analysis — Merck & Co Inc (NYSE:MRK) recently announced a total dividend of $0.85 per share, with the ex-dividend date set for 2026-09-15. This amount includes a $0.85 per share cash dividend payable on 2026-10-07.
Stocktwits 2026-09-15
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Yahoo Finance 2026-09-16
Oncology Tie-Up and Blockchain Pilot Might Change The Case For Investing In Merck (MRK)
Trefis 2026-09-16
Merck Stock: Is The $70 Billion Pipeline Worth the Premium? — A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.
Yahoo Finance 2026-09-16
What Is Pfizer (PFE) Really Getting From Its New ADC Licensing Deal?
Yahoo Finance 2026-09-16
1 Stock Under $50 to Target This Week and 2 That Underwhelm — Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
Yahoo Finance 2026-09-16
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Yahoo Finance 2026-09-16
Johnson & Johnson (JNJ) Reports Stronger Survival Data In EGFR Mutated Lung Cancer
24/7 Wall St. 2026-09-16
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees — Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.
Yahoo Finance 2026-09-16
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
Yahoo Finance 2026-09-16
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? — Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Yahoo Finance 2026-09-16
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies |
The Motley Fool 2026-09-16
Is AbbVie the Best Dividend King to Buy in September?
24/7 Wall St. 2026-09-16
How a Roth IRA Can Keep Thousands More of Your High-Yield Dividend Income Compounding
Yahoo Finance 2026-09-16
Creative Spirit Hosts 2026 "Gen Neu" Gala at the New York Stock Exchange, Unveils Workplace Technology Partnership
Yahoo Finance 2026-09-16
Tempo Therapeutics Closes Oversubscribed $14.5 Million Financing to Advance MAP(TM) Regenerative Technology
Yahoo Finance 2026-09-16
Why This Biotech Stock Just Got a Rare Double Upgrade
Trefis 2026-09-16
Is Pfizer's New Business Big Enough To Carry The Old One? — Pfizer (PFE) trades at about 95% of its 52-week high. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt.
Yahoo Finance 2026-09-16
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
Trefis 2026-09-16
Should You Judge JNJ Stock Without STELARA? — Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points.
Stocktwits 2026-09-16
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside — Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.
This Dividend Stock Is Beating the Market in 2026 and Yields 2.36% 2026-09-16
This Dividend Stock Is Beating the Market in 2026 and Yields 2.36% — Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.
J&J sells Laminar LAA closure assets it bought 3 years ago 2026-09-16
J&J sells Laminar LAA closure assets it bought 3 years ago
Yahoo Finance 2026-09-17
Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic
Yahoo Finance 2026-09-17
Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears
24/7 Wall St. 2026-09-17
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Yahoo Finance 2026-09-17
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Trefis 2026-09-17
What Happens To AbbVie Stock If SKYRIZI Slows Down? — AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink.
Yahoo Finance 2026-09-17
Merck (MRK) Outperforms Broader Market: What You Need to Know — Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day.
Yahoo Finance 2026-09-17
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know — In the most recent trading session, Johnson & Johnson (JNJ) closed at $270.22, indicating a +1.1% shift from the previous trading day.
Yahoo Finance 2026-09-17
PepsiCo Elects Joaquin Duato to Board of Directors
Yahoo Finance 2026-09-17
Merck Gains as Keytruda's Space Research Seeks a New Home
Trefis 2026-09-17
Is ISRG Stock Really As Expensive As It Looks? — Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high.
Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff 2026-09-17
Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff — Johnson & Johnson (NYSE:JNJ) Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility.
Yahoo Finance 2026-09-17
Moderna: Another Day, Another Big Stock Move. Is the Cancer Vaccine Rally Back On?
Trefis 2026-09-17
Why BSX Stock Lost More Than Half Its Value While Sales Kept Rising — Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%.
24/7 Wall St. 2026-09-17
How Much Do You Really Need Invested to Replace a $130,000 Salary With Dividends?
Yahoo Finance 2026-09-18
Johnson & Johnson (JNJ) Faces A Fresh Valuation Test On DePuy Sale Talk — A potential sale of DePuy Synthes for about US$20b has put Johnson & Johnson (JNJ) back in focus for investors watching how management reshapes its MedTech footprint and capital allocation priorities. The share price of Johnson & Johnson sits at US$270.22 after a 1-day share price return of 1.10% and a 90-day share price return of 18.32%.
The Motley Fool 2026-09-18
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
24/7 Wall St. 2026-09-18
Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing? — Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
Yahoo Finance 2026-09-18
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
Yahoo Finance 2026-09-18
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
24/7 Wall St. 2026-09-18
The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20 — Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift.
Trefis 2026-09-18
Can Intuitive Surgical Make Up For A Lower Price Per Surgery? — Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%.
Yahoo Finance 2026-09-18
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Yahoo Finance 2026-09-18
Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
Yahoo Finance 2026-09-18
All 50 States Joining Medicaid Drug Pricing Model After Pharma Deals, Trump Says
Trefis 2026-09-18
What Would It Take For Eli Lilly Stock To Keep Climbing? — Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars.
Trefis 2026-09-18
Merck Stock Nearly Doubled Without A Change In Its Revenue Growth — Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147.
Yahoo Finance 2026-09-18
What Does Merck (MRK) Mean For EU Bladder Cancer Treatment After CHMP Support?
The Motley Fool 2026-09-18
3 Dividend Stocks to Buy and Hold for 10 Years
Trefis 2026-09-18
Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price? — Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500.
Yahoo Finance 2026-09-19
PepsiCo (PEP) Adds A New Director, Is The Discount To Fair Value Warranted? — Recent trading has been rough for PepsiCo, with the share price falling 9.0% over the past 30 days and 8.8% year to date. The 1 year total shareholder return is down 4.8% and the 3 year total shareholder return has declined 17.5%,...
24/7 Wall St. 2026-09-19
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
Yahoo Finance 2026-09-19
Pfizer to Share Revenue With HHS in Deal on Overseas Drug Prices
24/7 Wall St. 2026-09-21
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher — A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen.
Yahoo Finance 2026-09-21
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Yahoo Finance 2026-09-21
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
Yahoo Finance 2026-09-21
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies
Trefis 2026-09-21
How Far Could ISRG Stock Bounce From Here? — Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.
Yahoo Finance 2026-09-21
Huge News For Pfizer Stock Fans
The Motley Fool 2026-09-21
Does Long-Term Dividend Investing Really Work? This Study Says "Definitely."
Trefis 2026-09-21
What Would It Take For Pfizer To Cut Its Dividend? — Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high.
Yahoo Finance 2026-09-21
J&J Gains as Caplyta Opens a Mania Expansion Path
Yahoo Finance 2026-09-21
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
Stocktwits 2026-09-21
Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’
Yahoo Finance 2026-09-21
How Investors Are Reacting To Pfizer (PFE) Easing Policy Pressures And New HHS Revenue-Sharing Deal
Proactive Investors 2026-09-21
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors — Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market.
Yahoo Finance 2026-09-21
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
Yahoo Finance 2026-09-21
Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles
Yahoo Finance 2026-09-21
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
Yahoo Finance 2026-09-21
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
Stocktwits 2026-09-21
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
Yahoo Finance 2026-09-21
Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
Yahoo Finance 2026-09-22
Moderna (MRNA) Stock Trades Up, Here Is Why — Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion 2026-09-22
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
Yahoo Finance 2026-09-22
Capitalize on the PEGylated Proteins Revenue Shift: Benchmark Amgen, Roche, Merck KGaA, Pfizer and Novo Nordisk to Secure Competitive ROI Through the Forecast Period — 22, 2026 (GLOBE NEWSWIRE) -- "PEGylated Proteins - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for PEGylated Proteins was estimated at US$2.0 Billion in 2025 and is projected to reach US$4.1 Billion by 2032, growing at a CAGR of 10.6% from 2
Yahoo Finance 2026-09-22
Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move First — 22, 2026 (GLOBE NEWSWIRE) -- "Orphan Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Orphan Drugs was valued at US$216.3 Billion in 2024 and is projected to reach US$426.2 Billion by 2030, growing at a CAGR of 12% from 2024 to 2030.
Yahoo Finance 2026-09-22
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
24/7 Wall St. 2026-09-22
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up? — Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide 2026-09-22
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Yahoo Finance 2026-09-22
What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For Shareholders
Yahoo Finance 2026-09-22
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
Trefis 2026-09-22
Could You Have Seen Merck Stock's Pipeline Run Coming? — Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%.
Trefis 2026-09-22
Why Is JNJ Stock Beating Rivals That Grow Faster? — Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies.
The Motley Fool 2026-09-22
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
Yahoo Finance 2026-09-22
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
Trefis 2026-09-22
How Far Can BSX Stock Swing After Losing More Than Half Its Value? — Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share.
Yahoo Finance 2026-09-22
What Could Johnson & Johnson (JNJ) Gain From Its New Immunology Push?
Yahoo Finance 2026-09-22
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
Yahoo Finance 2026-09-22
Why Is Merck (MRK) In Focus After Japan Cleared A New Dosing Option?
Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline 2026-09-22
Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline
Yahoo Finance 2026-09-22
AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization
Yahoo Finance 2026-09-22
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
24/7 Wall St. 2026-09-22
Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win 2026-09-22
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win — J&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.
Yahoo Finance 2026-09-22
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH,
Yahoo Finance 2026-09-23
Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now — Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil
Yahoo Finance 2026-09-23
3 Healthcare Stocks with Warning Signs — Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 38.9% over the past six months, topping the S&P 500 by 20.9 percentage points.
Yahoo Finance 2026-09-23
Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue — 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Breakthrough Therapy (BT) Designation was estimated at US$79.7 Billion in 2025 and is projected to reach US$212.5 Billion…
24/7 Wall St. 2026-09-23
These 6 High-Yield Dividends May Be Too Good to Be True
Trefis 2026-09-23
What Is The Best Case For Pfizer Stock?
24/7 Wall St. 2026-09-23
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Pfizer’s International Chief Just Explained How the Turnaround Actually Works. Here’s Where the Stoc 2026-09-23
Pfizer’s International Chief Just Explained How the Turnaround Actually Works. Here’s Where the Stock Could Go — Key Stats for Pfizer StockCurrent Price: $27. 93Target Price (Mid): ~$29Street Target: ~$29Potential Total Return: ~5%Annualized IRR: ~1.
Yahoo Finance 2026-09-23
Surgical Devices Market Size to Worth USD 27.14 Billion by 2030, at a CAGR of 14.7% – MarketsandMarkets™ — 23, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global surgical devices market will grow from USD 188.74 billion in 2026 to USD 296.76 billion by 2031, at a CAGR of 9.5% during the forecast period.
Yahoo Finance 2026-09-23
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early
24/7 Wall St. 2026-09-23
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout — Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.
Yahoo Finance 2026-09-23
Merck (MRK) Declines More Than Market: Some Information for Investors — In the latest trading session, Merck (MRK) closed at $148.08, marking a -1.88% move from the previous day.
Yahoo Finance 2026-09-23
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
Yahoo Finance 2026-09-23
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
Proactive Investors 2026-09-23
Merck pipeline seen driving potential re-rating as clinical catalysts approach
Trefis 2026-09-23
What Is AbbVie No Longer Telling You?
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID 2026-09-23
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
Yahoo Finance 2026-09-23
Merck Manuals Details What Patients Need to Know About Inflammatory Bowel Disease
Johnson & Johnson: What the Street’s Reaction to OTTAVA Actually Reveals About the Stock 2026-09-23
Johnson & Johnson: What the Street’s Reaction to OTTAVA Actually Reveals About the Stock — Key TakeawaysJohnson & Johnson’s MedTech segment, the business OTTAVA sits inside, grew from $7. 89 billion to $8.
24/7 Wall St. 2026-09-23
3 Dividend Stocks Trading Cheap Enough to Buy Meaningful Stakes for Under $1,000 — AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors nervous.
Yahoo Finance 2026-09-23
Crystalys Therapeutics Strengthens Board of Directors and Leadership Team as Dotinurad Advances Through Global Phase 3 Development
Yahoo Finance 2026-09-23
Top 3 AI Healthcare Stocks With Revenue Growth Up To 24%
Yahoo Finance 2026-09-23
Pfizer (PFE) Stock May Be Overvalued After Overseas Pricing Deal — Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the question is how much of the latest news and revenue mix shifts are already reflected in that figure.
Yahoo Finance 2026-09-24
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Yahoo Finance 2026-09-24
Medical Robots Market Forecasts Growth from $20.6B (2026) to $41.7B by 2031, Profiling Intuitive Surgical, Stryker, Zimmer Biomet & Medtronic — The global medical robots market is projected to grow from USD 20.6 billion in 2026 to USD 41.7 billion by 2031, at a 15.1% CAGR.
Merck reveals study success, and possible safety worries, for eye drug hopeful 2026-09-24
Merck reveals study success, and possible safety worries, for eye drug hopeful — A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.
Yahoo Finance 2026-09-24
AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors
Yahoo Finance 2026-09-24
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
Yahoo Finance 2026-09-24
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Yahoo Finance 2026-09-24
Merck (MRK), What Is Behind The Fresh Attention Now? — Merck’s recent FDA label update for WINREVAIR lands while the share price has climbed strongly over 2026, with a 90-day share price return of 18.04%, a year-to-date gain of 39.11%, and a 1-year total shareholder return of 91.32%, suggesting momentum has been...
Yahoo Finance 2026-09-24
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
What J&J’s Spravato patent win could mean for psychedelic drugs 2026-09-24
What J&J’s Spravato patent win could mean for psychedelic drugs
The Motley Fool 2026-09-24
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo Finance 2026-09-24
J&J’s RYBREVANT Shows Strong Survival. Is J&J’s Oncology Franchise Gaining?
Yahoo Finance 2026-09-24
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Yahoo Finance 2026-09-24
Apollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue — (NYSE:APO) is in discussions to acquire Johnson & Johnson (NYSE:JNJ)’s orthopedics business, DePuy Synthes, in a potential transaction valuing the unit at close to $20 billion, according to Bloomberg. The unit, which J&J previously announced plans to separate within an 18-to-24-month timeframe, generated $9.3 […]
Yahoo Finance 2026-09-24
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Yahoo Finance 2026-09-24
Merck Jumps as Winrevair Moves Earlier in PAH
Trefis 2026-09-24
Can Eli Lilly Stock Catch Up To Rivals It Outgrows? — Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly.
Trefis 2026-09-24
Can This Number Push ISRG Stock Higher? — Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%.
24/7 Wall St. 2026-09-24
Dave Ramsey Says You Need More Than 6% Just to Break Even. Dividend Growth Is One Way to Get There.
Yahoo Finance 2026-09-24
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
24/7 Wall St. 2026-09-24
CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More
Yahoo Finance 2026-09-24
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Yahoo Finance 2026-09-25
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth?
Yahoo Finance 2026-09-25
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Yahoo Finance 2026-09-25
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
Yahoo Finance 2026-09-25
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma — Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 CARTITUDE-2 study (N=20) showing that 50% of patients (10/20) in early line relapsed or refractory multiple myeloma (RRMM) who…
Yahoo Finance 2026-09-25
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Trefis 2026-09-25
Is LLY Stock Cheaper Than It Looks? — At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings.
Yahoo Finance 2026-09-25
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.
24/7 Wall St. 2026-09-25
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
24/7 Wall St. 2026-09-25
Own This Cigarette Stock Or Treasuries? — With the stock market leaning hard on one shaky pillar and U.S. debt crossing $40 trillion, a 57-year-old dividend stalwart from an industry everyone loves to hate might be the safest place to park your money right now.
Yahoo Finance 2026-09-25
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
24/7 Wall St. 2026-09-25
The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement
Proactive Investors 2026-09-25
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
The Motley Fool 2026-09-25
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool 2026-09-25
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
Yahoo Finance 2026-09-25
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
Trefis 2026-09-25
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
Quartz 2026-09-25
Merck remigromig DME trial results raise safety concerns
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data 2026-09-25
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry 2026-09-25
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
24/7 Wall St. 2026-09-26
Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns
Yahoo Finance 2026-09-27
Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks